"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 1998/020428 A1,188-903-538-296-217,1998-05-14,1998,US 9719912 W,1997-10-31,US 74271396 A,1996-11-01,INTERACTIVE AND AUTOMATIC PROCESSING OF TEXT TO IDENTIFY LANGUAGE BIAS,"A system (10) that interactively and automatically processes text to identify language bias has a text input (20), a central processing unit (CPU) (30), a memory (40) for storing bias codes, a memory (50) for storing words and phrases related to bias, and output apparatus (60) for presenting text output to a user. A computer-readable storage medium device (25) contains databases including a first database (26) of words expressing bias and a second database (27) including at least one alternative expression for each of the words expressing bias. The first database (26) has a bias-type code associated with each of the words expressing bias. The computer-readable storage medium may also include a third database (28) including help messages and/or training messages for language-bias education. Each of the provided computer-readable storage medium devices may be limited to one bias type or may include several bias types in the same device.",BLAND LINDA M;;WITTMANN DAVID,BLAND LINDA M;;WITTMANN DAVID,,https://lens.org/188-903-538-296-217,Patent Application,yes,4,3,1,1,0,G06F40/253,G06F17/27,,0,0,,,,PENDING
2,CN,A,CN 101505742 A,046-309-443-726-252,2009-08-12,2009,CN 200780030572 A,2007-06-20,US 81506406 P,2006-06-20,Beta acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on Acacia fractions, compounds, and extracts.",METAPROTEOMICS LLC,JEFFREY BLAND;;JENNAE HALL AMY;;VEERA KONDA;;LINDA PACIORETTY;;ANU DESAI,,https://lens.org/046-309-443-726-252,Patent Application,no,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
3,CN,A,CN 101573128 A,120-224-552-618-575,2009-11-04,2009,CN 200780030592 A,2007-06-20,US 81506406 P,2006-06-20,Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,JEFFREY BLAND;;JENNAE HALL AMY;;VEERA KONDA;;LINDA PACIORETTY;;ANU DESAI,,https://lens.org/120-224-552-618-575,Patent Application,no,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
4,CN,A,CN 101505770 A,022-976-656-513-400,2009-08-12,2009,CN 200780030528 A,2007-06-20,US 81506406 P,2006-06-20,Reduced isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,JEFFREY BLAND;;JENNAE HALL AMY;;VEERA KONDA;;LINDA PACIORETTY;;ANU DESAI,,https://lens.org/022-976-656-513-400,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/18;;A61K35/00,,0,0,,,,DISCONTINUED
5,US,A1,US 2010/0112099 A1,060-299-568-842-645,2010-05-06,2010,US 61224909 A,2009-11-04,US 61224909 A;;US 19838708 P,2008-11-04,PHYTOCHEMICAL COMPOSITIONS AND METHODS FOR ACTIVATING AMP-KINASE,"The present invention relates to AMPK activation utilizing phytochemicals, natural plant extracts and combinations. Disclosed are methods, compounds, and compositions comprising drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify myocyte, hepatocyte, adipocyte, cardiac or pancreatic physiology through activation of AMPK.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA;;BLAND JEFFREY S,METAPROTEOMICS LLC (2009-11-05),https://lens.org/060-299-568-842-645,Patent Application,yes,7,17,5,5,0,A61K36/9068;;A61K36/9068;;A61K36/185;;A61K36/185;;A61K36/22;;A61K36/22;;A61K36/27;;A61K36/27;;A61K36/33;;A61K36/33;;A61K36/35;;A61K36/35;;A61K36/48;;A61K36/48;;A61K36/61;;A61K36/61;;A61K36/71;;A61K36/71;;A61K36/73;;A61K36/73;;A61K36/738;;A61K36/738;;A61K36/82;;A61K36/82;;A61K36/87;;A61K36/87;;A61K36/9066;;A61K36/9066;;A61K38/018;;A61K38/018,A61K36/00;;A61K36/27;;A61K36/45;;A61K36/752;;A61K36/82;;A61K36/906;;A61K38/00,424/729;;424/725;;424/732;;424/736;;424/756;;514/2,1,1,061-035-426-217-462,10.1097/01.cej.0000236247.86360.db;;17554207,"Jo et al, Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells by Oligonol is mediated by Bcl-2 family regulation and MEK/ERK signaling. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), (2007 Aug) Vol. 16, No. 4, pp. 342-7.",DISCONTINUED
6,CN,A,CN 101505743 A,038-130-437-386-87X,2009-08-12,2009,CN 200780030611 A,2007-06-20,US 81506406 P,2006-06-20,Hexahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,JEFFREY BLAND;;JENNAE HALL AMY;;VEERA KONDA;;LINDA PACIORETTY;;ANU DESAI,,https://lens.org/038-130-437-386-87X,Patent Application,no,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
7,EP,A1,EP 2348868 A1,102-312-653-999-765,2011-08-03,2011,EP 09822521 A,2009-10-20,US 2009/0061232 W;;US 19718508 P,2008-10-22,NOVEL MITOCHONDRIAL UNCOUPLING METHODS AND COMPOSITIONS FOR ENHANCING ADIPOCYTE THERMOGENESIS,,METAPROTEOMICS LLC,BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,,https://lens.org/102-312-653-999-765,Patent Application,yes,0,0,5,5,0,A61K31/05;;A61K36/00;;A61P3/00;;A61P3/04;;A61K31/05;;A61K36/00,A61K36/00;;A61K31/05;;A61P3/04,,0,0,,,,DISCONTINUED
8,US,A1,US 2010/0215782 A1,050-057-171-128-406,2010-08-26,2010,US 58196709 A,2009-10-20,US 58196709 A;;US 19718508 P,2008-10-22,NOVEL MITOCHONDRIAL UNCOUPLING METHODS AND COMPOSITIONS FOR ENHANCING ADIPOCYTE THERMOGENESIS,"Disclosed are methods, compounds, and compositions comprising botanically based drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify adipocyte physiology to enhance thermogenesis and modify cytokine secretion.",METAPROTEOMICS LLC,BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,METAPROTEOMICS LLC (2010-05-10),https://lens.org/050-057-171-128-406,Patent Application,yes,3,5,5,5,0,A61K31/05;;A61K36/00;;A61P3/00;;A61P3/04;;A61K31/05;;A61K36/00,A61K36/00;;A61K31/05;;A61K31/12;;A61K31/235;;A61K36/185;;A61K36/38;;A61K36/48;;A61K36/72;;A61K36/82;;A61K36/899;;A61P3/00,424/729;;424/725;;424/730;;424/750;;424/775;;514/533;;514/679;;514/731;;514/733,0,0,,,,DISCONTINUED
9,EP,A4,EP 2349305 A4,098-876-086-095-700,2012-08-22,2012,EP 09825326 A,2009-11-04,US 2009/0063218 W;;US 19838708 P,2008-11-04,PHYTOCHEMICAL COMPOSITIONS AND METHODS FOR ACTIVATING AMP-KINASE,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S,,https://lens.org/098-876-086-095-700,Search Report,no,2,0,5,5,0,A61K36/9068;;A61K36/9068;;A61K36/185;;A61K36/185;;A61K36/22;;A61K36/22;;A61K36/27;;A61K36/27;;A61K36/33;;A61K36/33;;A61K36/35;;A61K36/35;;A61K36/48;;A61K36/48;;A61K36/61;;A61K36/61;;A61K36/71;;A61K36/71;;A61K36/73;;A61K36/73;;A61K36/738;;A61K36/738;;A61K36/82;;A61K36/82;;A61K36/87;;A61K36/87;;A61K36/9066;;A61K36/9066;;A61K38/018;;A61K38/018,A61K36/906;;A61K36/185;;A61K36/22;;A61K36/27;;A61K36/33;;A61K36/35;;A61K36/48;;A61K36/61;;A61K36/71;;A61K36/73;;A61K36/738;;A61K36/82;;A61K36/87;;A61K36/9066;;A61K36/9068;;A61K38/01,,4,2,100-612-860-896-162;;030-855-226-881-202,17010224;;10.1079/bjn20061849;;10.1016/j.fct.2007.09.085;;17950516,"DATABASE FSTA [online] INTERNATIONAL FOOD INFORMATION SERVICE (IFIS), FRANkFURT-MAIN, DE; 1 July 2007 (2007-07-01), AL-AMIN Z M ET AL: ""Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats."", XP002607593, Database accession no. FS-2007-07-Te1076;;B.H. ALI ET AL.: ""Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): A review of recent research"", FOOD AND CHEMICAL TOXICOLOGY, vol. 46, no. 2, February 2008 (2008-02-01), pages 409 - 420, XP022399084, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2007.09.085;;KADNUR VENKATACHALAPATHI SANJAY ET AL: ""BENIFICIAL EFFECTS OF ZINGIBER OFFICINALE ON EXPERIMENTALLY INDUCED OBESITY"", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY.ANNUAL MEETING. ABSTRACTS OF PAPERS, XX, XX, no. 4/05, 1 January 2004 (2004-01-01), XP009060482;;See also references of WO 2010053949A1",DISCONTINUED
10,WO,A1,WO 2010/048114 A1,054-056-267-609-58X,2010-04-29,2010,US 2009/0061232 W,2009-10-20,US 19718508 P,2008-10-22,NOVEL MITOCHONDRIAL UNCOUPLING METHODS AND COMPOSITIONS FOR ENHANCING ADIPOCYTE THERMOGENESIS,"Disclosed are methods, compounds, and compositions comprising botanically based drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify adipocyte physiology to enhance thermogenesis and modify cytokine secretion.",METAPROTEOMICS LLC;;BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,,https://lens.org/054-056-267-609-58X,Patent Application,yes,2,30,5,5,0,A61K31/05;;A61K36/00;;A61P3/00;;A61P3/04;;A61K31/05;;A61K36/00,A61K31/415;;A01N65/00,,0,0,,,,PENDING
11,WO,A1,WO 2010/053949 A1,106-502-187-388-942,2010-05-14,2010,US 2009/0063218 W,2009-11-04,US 19838708 P,2008-11-04,PHYTOCHEMICAL COMPOSITIONS AND METHODS FOR ACTIVATING AMP-KINASE,"The present invention relates to AMPK activation utilizing phytochemicals, natural plant extracts and combinations. Disclosed are methods, compounds, and compositions comprising drugs, medical foods, and dietary supplements for the prevention and treatment of metabolic disorders, in particular obesity, weight gain, insulin resistance syndromes, diabetes, fasting hyperlipidemia and osteoarthritis. More specifically, the invention relates to pharmaceutical therapeutic methods and compositions utilizing phytochemicals, natural plant extracts and combinations to modify myocyte, hepatocyte, adipocyte, cardiac or pancreatic physiology through activation of AMPK.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S,,https://lens.org/106-502-187-388-942,Patent Application,yes,1,4,5,5,0,A61K36/9068;;A61K36/9068;;A61K36/185;;A61K36/185;;A61K36/22;;A61K36/22;;A61K36/27;;A61K36/27;;A61K36/33;;A61K36/33;;A61K36/35;;A61K36/35;;A61K36/48;;A61K36/48;;A61K36/61;;A61K36/61;;A61K36/71;;A61K36/71;;A61K36/73;;A61K36/73;;A61K36/738;;A61K36/738;;A61K36/82;;A61K36/82;;A61K36/87;;A61K36/87;;A61K36/9066;;A61K36/9066;;A61K38/018;;A61K38/018,A61K36/906,,10,8,045-314-228-168-788;;004-680-619-030-690;;002-143-471-977-282;;035-548-173-988-090;;127-311-110-109-001;;023-545-898-771-543;;099-169-381-919-809;;014-410-987-998-622,18850225;;10.1007/s12263-007-0069-7;;pmc2478493;;10.1172/jci29044;;pmc1483147;;16823475;;16873680;;10.2337/db05-1188;;16966355;;10.1203/01.pdr.0000242301.64555.e2;;11511517;;10.1096/fj.00-0828fje;;11356798;;10.1152/jappl.2001.90.6.2319;;10.1038/oby.2008.50;;pmc7603837;;18421261;;18501116;;10.1111/j.1745-7254.2008.00807.x,"HWANG ET AL.: ""Resveratrol Protects ROS-Induced Cell Death by Activating AMPK in H9c2 Cardiac Muscle Cells."", GENES NUTR, vol. 2, 16 November 2007 (2007-11-16), pages 323 - 326, XP008146875;;LONG ET AL.: ""AMP-Activated Protein Kinase Signaling in Metabolic Regulation."", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 7, July 2006 (2006-07-01), pages 1776 - 1783, XP008077268;;ZANG ET AL.: ""Polyphenols Stimulate AMP-Activated Protein Kinase, Lower Lipids, and Inhibit Accelerated Atherosclerosis in Diabetic LDL Receptor-Deficient Mice."", DIABETES, vol. 55, August 2006 (2006-08-01), pages 2180 - 2191, XP008146877;;BRAUNER ET AL.: ""Expression of Uncoupling Protein 3 and GLUT4 Gene in Skeletal Muscle of Preterm Newboms: Possible Control by AMP-Activated Protein Kinase."", PEDIATRIC RESEARCH, vol. 60, no. 5, 2006, pages 569 - 575, XP008146876;;GARCIA-MARTINEZ ET AL.: ""Overexpression of UCP3 in Cultured Human Muscle Lowers Mitochondrial Membrane Potential, Raises ATP/ADP Ratio, and Favors Fatty Acid vs. Glucose Oxidation1."", THE FASEB JOURNAL, vol. 15, September 2001 (2001-09-01), pages 2033 - 2035, XP008146878;;HICKNER ET AL.: ""Fatty Acid Oxidation in African-American and Caucasian Women During Physical Activity."", JOURNAL OF APPLIED PHYSIOLOGY, vol. 90, 2001, pages 2319 - 2324, XP008146891;;D'EON ET AL.: ""Estradiol and the Estradiol Metabolite, 2-Hydroxyestradiol, Activate AMP- Activated Protein Kinase in C2C12 Myotubes."", OBESITY, vol. 16, 10 April 2008 (2008-04-10), pages 1284 - 1288, XP008146892;;DATABASE MEDLINE SHANG ET AL.: ""Resveratrol Improves Non-Alcoholic Fatty Liver Disease by Activating AMP- Activated Protein Kinase."", XP008146879, Database accession no. 18501116;;ACTA PHARMACOLOGICA SINICA, vol. 29, no. 6, June 2008 (2008-06-01), pages 698 - 706, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/18501116> [retrieved on 20091216];;See also references of EP 2349305A1",PENDING
12,AU,A1,AU 2009/307753 A1,114-857-520-403-951,2010-04-29,2010,AU 2009/307753 A,2009-10-20,US 19718508 P;;US 2009/0061232 W,2008-10-22,Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis,,METAPROTEOMICS LLC,BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,,https://lens.org/114-857-520-403-951,Patent Application,no,0,0,5,5,0,A61K31/05;;A61K36/00;;A61P3/00;;A61P3/04;;A61K31/05;;A61K36/00,A01N65/00;;A61K31/415,,0,0,,,,DISCONTINUED
13,EP,A4,EP 2348868 A4,105-633-289-130-065,2013-06-12,2013,EP 09822521 A,2009-10-20,US 2009/0061232 W;;US 19718508 P,2008-10-22,NOVEL MITOCHONDRIAL UNCOUPLING METHODS AND COMPOSITIONS FOR ENHANCING ADIPOCYTE THERMOGENESIS,,METAPROTEOMICS LLC,BABISH JOHN G;;PACIORETTY LINDA M;;TRIPP MATTHEW L;;BLAND JEFFREY S,,https://lens.org/105-633-289-130-065,Search Report,no,6,0,5,5,0,A61K31/05;;A61K36/00;;A61P3/00;;A61P3/04;;A61K31/05;;A61K36/00,A61K36/00;;A61K31/05;;A61P3/04,,3,2,004-717-126-450-212;;008-026-928-243-090,18403477;;pmc2453081;;10.1210/en.2008-0262;;11322961;;10.1016/s0014-5793(01)02376-6,"DATABASE WPI Week 200635, Derwent World Patents Index; AN 2006-335717, XP002695885;;WEISBERG STUART P ET AL: ""Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity."", ENDOCRINOLOGY JUL 2008, vol. 149, no. 7, July 2008 (2008-07-01), pages 3549 - 3558, XP002695886, ISSN: 0013-7227;;MORIN<A B> D ET AL: ""Curcumin induces the mitochondrial permeability transition pore mediated by membrane protein thiol oxidation"", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 495, no. 1-2, 20 April 2001 (2001-04-20), pages 131 - 136, XP004235777, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(01)02376-6",DISCONTINUED
14,AU,A1,AU 2009/313657 A1,144-354-957-222-030,2010-05-14,2010,AU 2009/313657 A,2009-11-04,US 19838708 P;;US 2009/0063218 W,2008-11-04,Phytochemical compositions and methods for activating AMP-kinase,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S,,https://lens.org/144-354-957-222-030,Patent Application,no,0,0,5,5,0,A61K36/9068;;A61K36/9068;;A61K36/185;;A61K36/185;;A61K36/22;;A61K36/22;;A61K36/27;;A61K36/27;;A61K36/33;;A61K36/33;;A61K36/35;;A61K36/35;;A61K36/48;;A61K36/48;;A61K36/61;;A61K36/61;;A61K36/71;;A61K36/71;;A61K36/73;;A61K36/73;;A61K36/738;;A61K36/738;;A61K36/82;;A61K36/82;;A61K36/87;;A61K36/87;;A61K36/9066;;A61K36/9066;;A61K38/018;;A61K38/018,A61K36/906,,0,0,,,,DISCONTINUED
15,EP,A1,EP 2349305 A1,017-473-392-290-446,2011-08-03,2011,EP 09825326 A,2009-11-04,US 2009/0063218 W;;US 19838708 P,2008-11-04,PHYTOCHEMICAL COMPOSITIONS AND METHODS FOR ACTIVATING AMP-KINASE,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S,,https://lens.org/017-473-392-290-446,Patent Application,yes,0,0,5,5,0,A61K36/9068;;A61K36/9068;;A61K36/185;;A61K36/185;;A61K36/22;;A61K36/22;;A61K36/27;;A61K36/27;;A61K36/33;;A61K36/33;;A61K36/35;;A61K36/35;;A61K36/48;;A61K36/48;;A61K36/61;;A61K36/61;;A61K36/71;;A61K36/71;;A61K36/73;;A61K36/73;;A61K36/738;;A61K36/738;;A61K36/82;;A61K36/82;;A61K36/87;;A61K36/87;;A61K36/9066;;A61K36/9066;;A61K38/018;;A61K38/018,A61K36/906;;A61K36/185;;A61K36/22;;A61K36/27;;A61K36/33;;A61K36/35;;A61K36/48;;A61K36/61;;A61K36/71;;A61K36/73;;A61K36/738;;A61K36/82;;A61K36/87;;A61K36/9066;;A61K36/9068;;A61K38/01,,15,0,,,"DATABASE TKDL [online] ""Mardvikamadyagunaah"", XP003026610, Database accession no. AT/2145;;DATABASE TKDL [online] ""Dawa Bara-e- Ziabetus"", XP003028752, Database accession no. MH1/2828;;DATABASE TKDL [online] ""Naga Bhasma Prayoga"", XP003029197, Database accession no. RG12/227A;;DATABASE TKDL [online] ""Guramara Arka"", XP003029198, Database accession no. RS21/433B;;DATABASE TKDL [online] ""Dawa -e- Ziabetus"", XP003029199, Database accession no. NA4/1522A;;DATABASE TKDL [online] ""Neerizhiuvu Noikku Choornam -4"", XP003027815, Database accession no. AM05/1639;;DATABASE TKDL [online] ""Mahasankhavati"", XP003029200, Database accession no. AK/980;;DATABASE TKDL [online] ""Draksa Sura"", XP003025311, Database accession no. RS6/866;;DATABASE TKDL [online] ""Madhvadraka Prayoga"", XP003028772, Database accession no. RS1/651;;DATABASE TKDL [online] ""Triphaladi Kasaya"", XP003029201, Database accession no. RS1/1148;;DATABASE TKDL [online] ""Sufoof Tukhm-e- Jamun"", XP003029202, Database accession no. AN2/226H2;;MOHAMMAD NAJMUL GHANI KHAN: ""Khazaain-al-Advia"", vol. II, 1911, pages: 241;;DATABASE TKDL [online] ""Ratha Pithanoi Kudineer 1"", XP003026612, Database accession no. BS01/77;;DATABASE TKDL [online] ""Kanakasavam"", XP003029011, Database accession no. SK03/423;;See also references of WO 2010053949A1",DISCONTINUED
16,AU,A1,AU 2006/326658 A1,150-415-073-566-691,2007-06-21,2007,AU 2006/326658 A,2006-12-07,US 74890705 P;;US 2006/0046770 W,2005-12-09,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,,METAPROTEOMICS LLC,BLAND JEFF;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;HALL AMY JENNAE;;BABISH JOHN G,,https://lens.org/150-415-073-566-691,Patent Application,no,0,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K36/73;;A61K36/285,,0,0,,,,DISCONTINUED
17,AU,A1,AU 2012/261769 A1,032-421-904-004-175,2013-01-24,2013,AU 2012/261769 A,2012-12-14,AU 2006/326658 A;;AU 2012/261769 A,2006-12-07,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"C:\NRIPoroUJLC\JARW16456 I DULC-14f12/I2 Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs. Hexahydrocolupulone 1 .- 0.!57 Spent Hops rom,'commmm e 1.1 Beta-Acids Leavtrvasimmi t 1.24 Alpha Acids rwn.: n mm t 1.45 Xanthohumol rLrizwa ;teThI | 1.46 Hexahydroisoalpha acids umam. _i__ essa 1_| rL( Tetrahydroisoalpha acids La4 w1t. aL_1.79 Rho-isoalpha acids 2..%rrtn : maairnu.-rwwaavam o--+-- 2.25 Isoalpha acids b m mla aim: 2.45 Indomethacin mmmuna____ .r:= 1.33 Troglitazone 745-.J -A14 Solvent Control r':- 2t. 1.00 0.00 0,50 1.00 1.50 2.00 2.50 3.00 Relative Nonpolar Lipid Content",METAPROTEOMICS LLC,HALL AMY JENNAE;;BLAND JEFF;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;BABISH JOHN G,,https://lens.org/032-421-904-004-175,Patent Application,no,0,0,2,2,0,,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61P5/48,,0,0,,,,DISCONTINUED
18,EP,A4,EP 1968559 A4,101-854-895-698-172,2013-08-07,2013,EP 06844984 A,2006-12-07,US 2006/0046770 W;;US 74890705 P,2005-12-09,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/101-854-895-698-172,Search Report,no,4,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61K36/80;;A61P5/48,,9,5,047-943-176-362-128;;052-991-319-447-83X;;043-765-604-673-025;;122-027-422-521-02X;;111-035-007-848-309,8778502;;10.1016/0378-8741(95)01329-6;;22557085;;pmc3330998;;10.1021/np020238w;;12502309;;10.1196/annals.1329.054;;15659827;;10.1016/s0308-8146(99)00260-5,"WANG X-S ET AL: ""Study on hypoglycemic polysaccharide from Centalla asiatica"", CHINESE PHARMACEUTICAL JOURNAL NOVEMBER 2005 CHINESE MEDICAL ASSOCIATION CN, vol. 40, no. 22, November 2005 (2005-11-01), pages 1697 - 1700, XP009170472;;SUBRAMONIAM A ET AL: ""EFFECTS OF ARTEMISIA PALLENS WALL. ON BLOOD GLUCOSE LEVELS IN NORMAL AND ALLOXAN-INDUCED DIABETIC RATS"", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 50, no. 1, 1 January 1996 (1996-01-01), pages 13 - 17, XP002038211, ISSN: 0378-8741, DOI: 10.1016/0378-8741(95)01329-6;;RANA T S ET AL: ""Studies on indigenous herbal remedies for diabetes mellitus in India"", BIOSIS,, 15 September 1990 (1990-09-15), XP002572903;;DATABASE WPI Week 200560, Derwent World Patents Index; AN 2005-583447, XP002699140;;DATABASE WPI Week 200519, Derwent World Patents Index; AN 2005-176026, XP002699141;;ARORA DEEPA ET AL: ""Immunomodulating effects of rasayana drugs in diabetics - a clinical study."", ANCIENT SCIENCE OF LIFE OCT 2002, vol. 22, no. 2, October 2002 (2002-10-01), pages 42 - 48, XP018015455, ISSN: 0257-7941;;HOU C C ET AL: ""Bacopaside III, bacopasaponin G, and bacopasides A, B, and C from Bacopa monniera"", MEDICINAL & AROMATIC PLANTS ABSTRACTS, SCIENTIFIC PUBLISHERS, SCIENTIFIC PUBLISHERS, NEW DELHI - INDIA, vol. 25, no. 4, 1 August 2003 (2003-08-01), XP018007587, ISSN: 0250-4367;;AGGARWAL BHARAT B ET AL: ""Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals - Reasoning for seasoning"", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 1030, 1 December 2004 (2004-12-01), pages 434 - 441, XP009097664, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1329.054;;OOMAH B DAVE ET AL: ""Characteristics of raspberry (Rubus idaeus L.) seed oil"", FOOD CHEMISTRY, vol. 69, no. 2, March 2000 (2000-03-01), pages 187 - 193, XP002699143, ISSN: 0308-8146",DISCONTINUED
19,WO,A3,WO 2007/070355 A3,073-632-356-570-412,2008-07-03,2008,US 2006/0046770 W,2006-12-07,US 74890705 P,2005-12-09,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,"Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/073-632-356-570-412,Search Report,yes,6,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61P5/48,,10,9,115-121-723-074-734;;026-843-848-301-062;;042-704-235-643-115;;179-560-386-136-784;;050-747-009-682-300;;043-462-266-695-978;;109-097-981-177-440;;025-984-992-116-892;;133-000-470-545-834,10.3136/fstr.10.290;;10350364;;10.1016/s0378-8741(98)00141-x;;11666119;;10.1177/000331970105202s06;;15686403;;10.1021/jf048615t;;10563881;;10.1021/jf980624c;;15088689;;10.1074/jbc.m403456200;;15178687;;15852044;;10.1038/sj.ijo.0802965;;10.1001/jama.281.21.2005;;10359389,"DATABASE CAPLS [online] FUKUCHI Y. ET AL.: ""6-methylsulfinylhexyl isothiocyanate, an antioxidant derived from Wasabia japonica MATUM, ameliorates diabetic nephropathy in type 2 diabetic mice"", XP008118668, Database accession no. (2005:287685);;SHUKLA A. ET AL.: ""In vitro and in vivo wound healing activity of asiaticoside isolated from Centella asiatica"", JOURNAL OF ETHNOPHARMACOLOGY, vol. 65, no. 1, April 1999 (1999-04-01), pages 1 - 11, XP002240115;;INCANDELA L. ET AL.: ""Treatment of diabetic microangiopathy and edema with total triterpenic fraction of Centella asiatica: a prospective, placebo-controlled randomized study"", ANGIOLOGY, vol. 52, no. SUPPL. 2, October 2001 (2001-10-01), pages S27 - S31, XP008077151;;PARRY J. ET AL.: ""Fatty acid composition and antioxidant properties of cold-pressed marionberry, boysenberry, red raspberry, and blueberry seed oils"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 53, no. 3, 9 February 2005 (2005-02-09), pages 566 - 573;;MALLAVARAPU G.R. ET AL.: ""Influence of plant growth stage on the essential oil content and composition in Davana (Artemisa pallens wall.)"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 47, no. 1, January 1999 (1999-01-01), pages 254 - 258, XP008128743;;DATABASE PUBMED [online] DORABABU M. ET AL.: ""Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experimental NIDDM rats"", XP008117907, Database accession no. (15088689);;YAJIMA H. ET AL.: ""Isohumulones, bitter acids derived from Hops, activate both peroxisome proliferators-activated receptor alpha and gamma and reduce insulin resistance"", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 32, August 2004 (2004-08-01), pages 33456 - 33462, XP008128745;;YAJIMA H. ET AL.: ""Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents"", INTERNATIONAL JOURNAL OF OBESITY, vol. 29, no. 8, August 2005 (2005-08-01), pages 991 - 997, XP008128842;;TURNER R.C. ET AL.: ""Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies"", (UKPDS 49). UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. JAMA, vol. 281, no. 21, 2 June 1999 (1999-06-02), pages 2005 - 2012, XP008011494;;See also references of EP 1968559A4",PENDING
20,EP,A2,EP 1968559 A2,140-251-212-136-501,2008-09-17,2008,EP 06844984 A,2006-12-07,US 2006/0046770 W;;US 74890705 P,2005-12-09,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/140-251-212-136-501,Patent Application,yes,0,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61K36/80;;A61P5/48,,0,0,,,,DISCONTINUED
21,EP,A2,EP 2737897 A2,047-989-750-857-058,2014-06-04,2014,EP 14000382 A,2006-12-07,US 74890705 P;;EP 06844984 A,2005-12-09,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"The present invention relates to compositions consisting essentially of a therapeutically effective amount of a compound selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-isoadhumulone; and metformin, to be used in the treatment of an insulin related disorder, diabetes, obesity, or a cardiovascular disease.
",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/047-989-750-857-058,Patent Application,yes,0,1,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/122;;A61K31/015;;A61K31/12;;A61K31/155;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/10;;A61P9/00,,70,61,025-140-596-126-087;;067-903-390-436-000;;023-917-067-879-742;;050-800-835-295-273;;033-359-967-508-049;;050-808-527-160-242;;006-081-068-931-190;;139-115-297-986-094;;023-525-431-697-257;;075-932-559-528-430;;122-547-387-443-669;;022-398-348-990-879;;032-340-365-936-496;;045-121-842-365-932;;059-545-073-315-419;;001-303-442-581-661;;025-790-099-087-712;;100-055-928-181-667;;004-307-385-148-606;;158-116-197-080-889;;082-241-838-035-760;;031-298-360-739-562;;029-608-816-283-612;;031-698-912-935-100;;026-142-290-459-503;;026-800-328-387-990;;065-299-006-457-691;;034-978-183-589-759;;133-000-470-545-834;;055-132-496-804-555;;038-968-847-687-324;;094-894-668-205-424;;134-586-832-626-293;;100-238-915-069-352;;047-266-677-956-308;;092-274-364-034-427;;080-161-809-305-618;;027-415-606-777-389;;144-447-364-612-028;;053-139-290-959-737;;006-537-539-908-521;;102-071-695-047-127;;108-903-973-559-163;;108-903-973-559-163;;064-023-687-827-964;;048-812-779-123-026;;014-246-586-671-598;;048-398-498-525-431;;049-987-836-527-31X;;014-354-136-199-765;;014-616-548-039-132;;027-580-801-485-719;;008-227-583-763-402;;038-372-423-749-600;;011-300-160-316-666;;048-812-779-123-026;;130-643-811-466-094;;000-679-944-953-68X;;082-857-044-481-107;;109-097-981-177-440;;056-084-479-750-455,14698276;;10.1016/j.it.2003.10.013;;10.1007/s11892-002-0019-0;;12643190;;5318831;;10.2337/diab.14.10.619;;11842281;;10.1159/000048868;;12397372;;10.1007/s00441-002-0628-6;;10.1161/01.cir.0000124718.99562.91;;15037525;;10.1097/00006676-200207000-00008;;12131767;;10.1006/bbrc.2000.2959;;10873667;;10.1074/jbc.m410978200;;15471850;;8594615;;10.3181/00379727-211-43950d;;8764139;;10.1152/ajpcell.1996.270.6.c1581;;pmc198552;;10.1172/jci11830;;11134171;;11533494;;10.1126/science.1061620;;4847247;;pmc301558;;10.1172/jci107766;;10.1172/jci108827;;pmc372420;;330566;;10.2337/diabetes.47.9.1379;;9726224;;10.1172/jci4852;;10449443;;pmc408519;;7678183;;10.1126/science.7678183;;10195925;;10.1161/01.atv.19.4.972;;10.1210/jc.82.12.4196;;10.1210/jcem.82.12.4450;;9398739;;8616916;;10.1161/01.cir.93.1.106;;pmc295809;;10.1172/jci117899;;7738178;;10.1016/s1262-3636(07)70084-8;;15029093;;10.1210/rp.56.1.265;;11237217;;10.2165/00003495-199754030-00001;;9279500;;10.2165/00002018-199512010-00003;;7741982;;11790216;;10.1001/jama.287.3.360;;10.1074/jbc.m300423200;;12714600;;10.1001/jama.281.21.2005;;10359389;;11685828;;11683857;;10.1046/j.1463-1326.2001.00033.x;;15533633;;10.1016/j.mehy.2004.03.036;;10859688;;10.1054/mehy.1999.0952;;965073;;10.1002/(sici)1099-1573(199912)13:8<683::aid-ptr534>3.3.co;2-o;;10.1002/(sici)1099-1573(199912)13:8<683::aid-ptr534>3.0.co;2-x;;10594939;;10.1142/s0192415x00000155;;10794124;;12625217;;10.1093/ajhp/60.4.356;;10.1080/10408690490424694;;15116756;;10.1016/s0367-326x(00)00168-4;;11449517;;10.1002/cbic.200300749;;15185362;;15863912;;10.1248/bpb.28.937;;15656875;;10.1111/j.1365-2796.2004.01426.x;;6382953;;10.1016/0065-2571(84)90007-4;;pmc22126;;10377455;;10.1073/pnas.96.13.7563;;pmc22126;;10377455;;10.1073/pnas.96.13.7563;;10.1093/nar/11.5.1475;;pmc325809;;6828386;;10.1006/bbrc.2001.6307;;11798186;;10.1210/mend.16.5.0825;;11981038;;10.1210/me.16.5.1040;;15386813;;10.1002/dmrr.493;;10.1016/s0021-9150(97)00315-8;;9694545;;10.1074/jbc.m103241200;;11533050;;11334421;;10.2337/diabetes.50.5.1158;;10.1210/jc.86.8.3815;;11502817;;10.1210/jcem.86.8.7741;;10.2337/diabetes.46.1.3;;8971073;;10.2337/diab.46.1.3;;10.1080/713782132;;10.1080/ann.34.3.217.224;;12173692;;6181064;;10.1016/s0021-9258(18)33704-9;;10.1006/bbrc.2001.6307;;11798186;;10.1038/1841296b0;;14402470;;8834766;;10.1007/bf00202068;;15892652;;10.2174/1566524053766022;;10.1074/jbc.m403456200;;15178687;;2692037,"DANDONA, P. ET AL.: ""Inflammation: the link between insulin resistance, obesity and diabetes"", TRENDS IMMUNOL., vol. 25, no. 1, 2004, pages 407;;DANDONA, P.: ""Endothelium, inflammation, and diabetes"", CURR DIAB REP, vol. 2, no. 4, 2002, pages 311 - 315;;GEPTS, W.: ""Pathologic anatomy of the pancreas in juvenile diabetes mellitus"", DIABETES, vol. 14, 1965, pages 619 - 633;;KOLIOPANOS, A. ET AL.: ""Cyclooxygenase 2 expression in chronic pancreatitis: Correlation with stage of the disease and diabetes mellitus"", DIGESTION, vol. 64, 2001, pages 240 - 247;;LUO, C. ET AL.: ""Cellular distribution and contribution of cyclooxygenase (COX)-2 to diabetogenesis in NOD mouse"", CELL TISSUE RES., vol. 310, 2002, pages 169 - 175;;HELMERSSON, J. ET AL.: ""Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population"", CIRCULATION, vol. 109, 2004, pages 1729 - 1734;;SCHLOSSER, W. ET AL.: ""Cyclooxygenase-2 is overexpressed in chronic pancreatitis"", PANCREAS, vol. 25, no. 1, 2002, pages 26 - 30;;TABATABAI, T. ET AL.: ""COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin treated mice"", BIOCHEM. AND BIOPHYS. RES. COMM., vol. 273, 2000, pages 699 - 704;;HEITMEIER, M.R. ET AL.: ""Role of cyclooxygenase-2 in cytokine-induced (3-cell dysfunction and damage by isolated rat and human islets."", J. BIO. CHEM., vol. 279, no. 51, 2004, pages 53145 - 53151;;MCDANIEL, M.L. ET AL.: ""Cytokines and nitric oxide in islet inflammation and diabetes"", PROC. SOC. EXP. BIOL. MED., vol. 211, 1996, pages 24 - 32;;CORBETT, J.A. ET AL.: ""Tyrosine kinase inhibitors prevent cytokine-induced expression of iNOS and COX-2 by human islets"", AM J PHYSIOL., vol. 270, June 1996 (1996-06-01), pages C1581 - 7;;TAK, P.P.; FIRESTEIN, G.S.: ""NF-KB: a key role in inflammatory diseases"", J. CLIN. INVEST., vol. 107, 2001, pages 7 - 11;;YUAN, M. ET AL.: ""Reversal of obesity- and diet-induced insulin resistance with . salicylates or targeted disruption of I???"", SCIENCE, vol. 293, 2001, pages 1673 - 1677;;ROBERTSON, R.P. ET AL.: ""Inhibition of. in vivo insulin secretion by prostaglandin E"", J. CLIN. INVEST., vol. 54, 1974, pages 310 - 315;;ROBERTSON, R.P.; CHEN, M.: ""A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus"", J. CLIN. INVEST., vol. 60, 1977, pages 747 - 753;;ROBERTSON, R.P.: ""Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis"", DIABETES, vol. 47, 1998, pages 1379 - 1383;;LITHERLAND, S.A. ET AL.: ""Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus"", J. CLIN. INVEST., vol. 104, 1999, pages 515 - 523;;HOTAMISLIGIL G.S. ET AL.: ""Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance"", SCIENCE, vol. 259, 1993, pages 87 - 91;;YUDKIN, J.S. ET AL.: ""C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?"", ARTERIOSCLER. THROMB. VASC. BIOL., vol. 19, 1999, pages 972 - 978;;MOHAMED-ALI, V. ET AL.: ""Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-a, in 1;'ivo"", ENDOCRINOL. METAB., vol. 82, 1997, pages 4196 - 4200;;LUNDGREN, C.H. ET AL.: ""Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease"", CIRCULATION, vol. 93, 1996, pages 106 - 110;;KERN, P.A. ET AL.: ""The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase"", J. CLIN. INVEST., vol. 95, 1995, pages 2111 - 2119;;GUERRE-MILLO, M.: ""Adipose tissue and adipokines: for better or worse"", DIABETES METABOLISM, vol. 30, 2004, pages 13 - 19;;LEBOVITZ, H.E.; BANERJI, M.A.: ""Insulin resistance and its treatment by thiazolidinediones"", RECENT PROG HORM RES., vol. 56, 2001, pages 265 - 94;;SCHEEN, A.J.: ""Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments"", DRUGS, vol. 54, no. 3, September 1997 (1997-09-01), pages 355 - 368;;SCHEEN, A.J.; LEFEBVRE, P.J.: ""Antihyperglycaemic agents. Drug interactions of clinical importance"", DRUG SAF, vol. 12, no. 1, January 1995 (1995-01-01), pages 32 - 45;;INZUCCHI, S.E.: ""Oral antihyperglycemic therapy for type 2 diabetes: scientific review"", JAMA, vol. 287, no. 3, 16 January 2002 (2002-01-16), pages 360 - 372;;GAO, Z. ET AL.: ""Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases"", J. BIO. CHEM., vol. 278, no. 27, 2003, pages 24944 - 24950;;TURNER, R.C.; CULL, C.A.; FRIGHI, V.; HOLMAN, R.R.: ""Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group"", JAMA, vol. 281, no. 21, 2 June 1999 (1999-06-02), pages 2005 - 2012;;ZINMAN, B.: ""PPARgamma agonists in type 2 diabetes: how far have we come in preventing the inevitable'?"", A REVIEW OF THE METABOLIC EFFECTS OFROSIGLITAZONE. DIABETES OBES METAB., vol. 3, no. 1, August 2001 (2001-08-01), pages 34 - 43;;MCCARTY, M.F.: ""Nutraceutical resources for diabetes prevention--an update"", MED HYPOTHESES, vol. 64, no. 1, 2005, pages 151 - 1.58;;MCCARTY, M.F.: ""Toward practical prevention of type 2 diabetes"", MED HYPOTHESES, vol. 54, no. 5, May 2000 (2000-05-01), pages 786 - 793;;SINGH, K.N. ET AL.: ""Hypoglycaemic activity of Acacia catechu, Acacia suma, and Albizzia odoratissima seed diets in normal albino rats"", IND. J. MED. RES, vol. 64, 1976, pages 754 - 757;;AMOS, S.: ""The pharmacological effects of an aqueous extract from Acacia nilotica seeds"", PHYTOTHER. RES., vol. 13, 1999, pages 683 - 685;;AL-MUSTAFA, Z.H.; DAFALLAH, A.A.: ""A study on the toxicology ofAcacia nilotica"", AM. J. CLIN. MED., vol. 28, no. 1, 2000, pages 23 - 29;;BASCH, E. ET AL.: ""Bitter melon (Momordica chanantia): A review of efficacy and safety"", AM J HEALTH-SYST PHARM, vol. 60, 2003, pages 356 - 359;;ESHUN, K.: ""Aloe vera: a valuable ingredient for the food, pharmaceutical and cosmetic industries--a review"", CRIT REV FOOD SCI NUTR., vol. 44, no. 2, 2004, pages 91 - 96;;PUJAR, P.P. ET AL., A NEW GERMACRANOLIDE FROM ARTEMISIA PALLENS FITOTERAPIA, vol. 71, 2000, pages 590 - 592;;BRAHMACHARI, G.: ""Neem--an omnipotent plant: a retrospection"", CHEMBIOCHEM, vol. 5, no. 4, 2 April 2004 (2004-04-02), pages 408 - 421;;KURODA, M.; MIMAKI, Y. ET AL.: ""Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice"", BIOL PHARM BULL, vol. 28, no. 5, 2005, pages 937 - 939;;TRUJILLO, M.E; SCHERER, P.E.: ""Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome"", JOURNAL OF INTERNAL MEDICINE, vol. 257, 2005, pages 167 - 175;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Handbook of Molecular and Cellular Methods in Biology in Medicine"", 1995, CRC PRESS;;""Directed Mutagenesis: A Practical Approach"", 1991, IRL PRESS;;GOODMAN; GILMAN'S: ""The Pharmacological Basis of Therapeutics"", 2001, MCGRAW HILL COMPANIES INC.;;""Harrison's Principles of Internal Medicine"", 1994, MCGRAW HILL COMPANIES INC;;VERZELE, M.; DE KEUKELEIRE, D.: ""Developments in Food Science 27: Chemistry and Analysis of Hop and Beer Bitter Acids"", 1991, ELSEVIER SCIENCE PUB. CO.;;MEINER, C.L.: ""Monographs in Epidemiology and Biostatistics"", vol. 8, 1986, OXFORD UNIVERSITY PRESS, article ""Clinical Trials: Design, Conduct, and Analysis"";;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING CO.;;REMINGTON: ""The Science and Practice of Pharmacy"", 1995, LIPPINCOTT, WILLIAMS & WILKINS;;CHOU, T.C.; P. TALALAY: ""Quantitative analysis of dose-effect relationships; the combined effects of multiple drugs or enzyme inhibitors"", ADV ENZYME REGUL, vol. 22, 1984, pages 27 - 55;;WARNER, T.D. ET AL.: ""Nonsteroidal drug selectivities for cyclo-oxygenase- rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis"", PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 7563 - 7568;;WARNER ET AL.: ""Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo- oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis"", PROC NATL ACAD SCI U S A, vol. 96, 1999, pages 7563 - 7568;;DIGNAM ET AL., NUCL ACIDS RES, vol. 11, 1983, pages 1475 - 1489;;FASSHAUER, M.; KLEIN, J.; NEUMANN, S.; ESZLINGER, M.; PASCHKE, R.: ""Hormonal regulation of adiponectin gene expression in 3T3-Ll adipocytes"", BIOCHEM BIOPHYS RES COMMUN, vol. 290, 2002, pages 1084 - 1089;;LI, Y.; LAZAR, M. A.: ""Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2"", MOL ENDOCRINOL, vol. 16, 2002, pages 1040 - 1048;;RAZ, I.; ELDOR, R.; CERNEA, S.; SHAFRIR, E: ""Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage"", DIABETES METAB RES REV, vol. 21, 2005, pages 3 - 14;;MARTIN, G.; K. SCHOONJANS ET AL.: ""PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes"", ATHEROSCLEROSIS, vol. 137, 1998, pages 75 - 80;;YAMAUCHI, T.; J. KAMON ET AL.: ""The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance"", J BIOL CHEM, vol. 276, no. 44, 2001, pages 41245 - 54;;OAKES, N. D.; G. THALEN ET AL.: ""Thiazolidinediones increase plasma- adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability"", DIABETES, vol. 50, no. 5, 2001, pages 1158 - 65;;YANG, W. S.; W. J. LEE ET AL.: ""Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin"", J CLIN ENDOCRINOL METAB, vol. 86, no. 8, 2001, pages 3815 - 9;;BODEN, G.: ""Role of fatty acids in the pathogenesis of insulin resistance and NIDDM"", DIABETES, vol. 46, no. 1, 1997, pages 3 - 10;;STUMVOLL, M.; H. U. HARING: ""Glitazones: clinical effects and molecular mechanisms"", ANN MED, vol. 34, no. 3, 2002, pages 217 - 24;;KASTURI, R.; JOSHI, V. C.: ""Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-Ll cells"", J BIOL CHEM, vol. 257, 1982, pages 12224 - 12230;;FASSHAUER ET AL.: ""Hormonal regulation of adiponectin gene expression in 3T3-Ll adipocytes"", BBRC, vol. 290, 2002, pages 1084 - 1089;;HOFSTEE, B.H.: ""Non-inverted versus inverted plots in enzyme kinetics"", NATURE, vol. 184, 1959, pages 1296 - 1298;;HIBI, M.; NAKAJIMA, K.; HIRANO T.: ""IL-6 cytokine family and signal transduction: a model of the cytokine system"", J MOL MED., vol. 74, no. 1, January 1996 (1996-01-01), pages 1 - 12;;ARNER, P.: ""Insulin resistance in type 2 diabetes - role of the adipokines"", CURR MOL MED., vol. 5, no. 3, May 2005 (2005-05-01), pages 333 - 9;;YAJIMA, H.; IKESHIMA, E.; SHIRAKI, M.; KANAYA, T.; FUJIWARA, D.; ODAI, H.; TSUBOYAMA-KASAOKA, N.; EZAKI, O.; OIKAWA, S.; KONDO, K.: ""Isobumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance"", J BIOL CHEM, vol. 279, 2004, pages 33456 - 33462;;BERENBAUM, M. C.: ""What is synergy?"", PHARMACOL REV, vol. 41, no. 2, 1989, pages 93 - 141",DISCONTINUED
22,WO,A2,WO 2007/070355 A2,153-015-208-578-208,2007-06-21,2007,US 2006/0046770 W,2006-12-07,US 74890705 P,2005-12-09,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,"Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/153-015-208-578-208,Patent Application,yes,0,6,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K36/73;;A61K36/285,,1,0,,,See references of EP 1968559A4,PENDING
23,AU,A1,AU 2012/265557 A1,055-316-839-914-42X,2013-01-31,2013,AU 2012/265557 A,2012-12-17,AU 2006/326658 A;;AU 2012/265557 A,2006-12-07,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"C: \NRPortbl\DCC\DAR\489270_l.DOC-17 12/2012 Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs. Hexahydrocolupulone _-^-7.1 0.57 Spent Hops : 1.11 Beta-Acids 1 .24 Alpha Acids sw ____ _ -' 1 1.45 -_- I _ _ ii _ Xanthohumol rrImm mm - 1.46 Hexahydroisoalpha acids Ir:"".E 2 Tetrahydroisoalpha acids I m z m4 : 1.79 __I 'i__ f_ W Rho-isoaipha acids 2.25 Isoaipha acids -____ ____ 2.45 Indomethacin m_ _ ________ . 1.33 Troglitazone - --1 1.43 Solvent Control a 1.00 0.00 0.50 1.00 1.50 2.00 2.50 3.00 Relative Nonpolar Lipid Content WO 2007/070355 PCT/US2006/046770 Hexahydrocolupulone kv e L7.I 10.57 Spent Hops m re me m:I 1.11 Beta-Acids 1 m Thw's = - .24 Alpha Acids m n a m 1.45 Xanthohumol r a m a i -1 1.46 Hexahydroisoalpha acids amme-,r sa.a : - 1. 2 Tetrahydroisoalpha acids a mae r1- 1.79 Rho-isoalpha acids a -:"" _________ : 2.25 Isoalpha acids a ____________n: 4 2.45 Indomethacin m22, mm5mfer : 1.33 Troglitazone 7,7 .7 77m75,777:77 i 1.43 Solvent Control mi - n ~ 1.00 0.00 0.50 1.00 1.50 2.00 2.50 3.00 Relative Nonpolar Lipid Content Fig. 18",METAPROTEOMICS LLC,HALL AMY JENNAE;;BLAND JEFF;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;BABISH JOHN G,,https://lens.org/055-316-839-914-42X,Patent Application,no,0,0,2,2,0,,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61P5/48,,0,0,,,,DISCONTINUED
24,CA,A1,CA 2632607 A1,043-490-305-462-842,2007-06-21,2007,CA 2632607 A,2006-12-07,US 74890705 P;;US 2006/0046770 W,2005-12-09,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,,METAPROTEOMICS LLC,BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;BABISH JOHN G;;TRIPP MATTHEW L,,https://lens.org/043-490-305-462-842,Patent Application,no,0,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/01;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/68;;A61K36/73;;A61P5/48,,0,0,,,,DISCONTINUED
25,EP,A3,EP 2737897 A3,145-736-443-674-830,2014-10-01,2014,EP 14000382 A,2006-12-07,US 74890705 P;;EP 06844984 A,2005-12-09,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"The present invention relates to compositions consisting essentially of a therapeutically effective amount of a compound selected from the group consisting of tetrahydro-isohumulone, tetrahydro-isocohumulone, and tetrahydro-isoadhumulone; and metformin, to be used in the treatment of an insulin related disorder, diabetes, obesity, or a cardiovascular disease.
",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFF;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA,,https://lens.org/145-736-443-674-830,Search Report,yes,9,0,9,124,0,A61K36/282;;A61K31/015;;A61K31/12;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/06;;A61P3/10;;A61P5/48;;A61P9/00;;A61P9/10;;A61P9/12;;A61P29/00;;A61P35/00,A61K31/122;;A61K31/015;;A61K31/12;;A61K31/155;;A61K31/353;;A61K36/185;;A61K36/23;;A61K36/235;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/04;;A61P3/10;;A61P9/00,,2,2,109-097-981-177-440;;025-984-992-116-892,10.1074/jbc.m403456200;;15178687;;15852044;;10.1038/sj.ijo.0802965,"YAJIMA H ET AL: ""Isohumulones, bitter acids derived from Hops, activate both peroxisome proliferators-activated receptor alpha and gamma and reduce insulin resistance"", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 32, 6 August 2004 (2004-08-06), pages 33456 - 33462, XP008128745, ISSN: 0021-9258, [retrieved on 20040603], DOI: 10.1074/JBC.M403456200;;YAJIMA H ET AL: ""Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents"", INTERNATIONAL JOURNAL OF OBESITY, NEWMAN PUBLISHING, LONDON, GB, vol. 29, no. 8, 1 August 2005 (2005-08-01), pages 991 - 997, XP008128842, ISSN: 0307-0565, [retrieved on 20050419], DOI: 10.1038/SJ.IJO.0802965",DISCONTINUED
26,KR,A,KR 20090023719 A,061-945-507-646-181,2009-03-05,2009,KR 20097001246 A,2009-01-20,US 81506406 P,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/061-945-507-646-181,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122;;A61P35/00,,0,0,,,,DISCONTINUED
27,WO,A2,WO 2007/149480 A2,157-199-517-578-062,2007-12-27,2007,US 2007/0014372 W,2007-06-20,US 81506406 P,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/157-199-517-578-062,Patent Application,yes,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
28,WO,A2,WO 2007/149505 A2,194-316-417-369-898,2007-12-27,2007,US 2007/0014414 W,2007-06-20,US 81506406 P,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/194-316-417-369-898,Patent Application,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
29,WO,A3,WO 2007/149505 A3,006-941-654-292-202,2008-05-02,2008,US 2007/0014414 W,2007-06-20,US 81506406 P,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/006-941-654-292-202,Search Report,yes,1,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,PENDING
30,EP,A4,EP 2043621 A4,000-599-968-577-543,2009-08-26,2009,EP 07796314 A,2007-06-20,US 2007/0014450 W;;US 81506406 P,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/000-599-968-577-543,Search Report,no,1,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
31,WO,A3,WO 2007/067812 A3,045-916-540-113-261,2008-02-28,2008,US 2006/0047196 W,2006-12-11,US 74893105 P,2005-12-09,PROTEIN KINASE MODULATION BY HOPS AND ACACIA PRODUCTS,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/045-916-540-113-261,Search Report,yes,5,0,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K38/43;;A61K36/00,,3,2,017-776-280-596-756;;030-746-354-453-058,12670534;;10.1016/s1074-5521(03)00048-6;;15231405;;10.1016/j.phytochem.2004.04.025,"WARD ET AL.: ""Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors"", CHEMISTRY & BIOLOGY, vol. 10, March 2003 (2003-03-01), pages 207 - 213, XP002289830;;STEVENS ET AL.: ""Xanthohumol and Related Prenylflavonoids from Hops and Beer: to your good health"", PHYTOCHEMISTRY, vol. 65, May 2004 (2004-05-01), pages 1317, XP004517844;;See also references of EP 1976552A4",PENDING
32,KR,A,KR 20090023722 A,062-628-212-089-151,2009-03-05,2009,KR 20097001254 A,2009-01-20,US 81506406 P,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/062-628-212-089-151,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/12;;A61P35/00,,0,0,,,,DISCONTINUED
33,NZ,A,NZ 568860 A,060-329-599-751-599,2012-09-28,2012,NZ 56886006 A,2006-12-11,US 74893105 P;;US 2006/0047196 W,2005-12-09,Protein kinase modulation by hops and acacia products,"Disclosed is the use of a composition in the manufacture of a medicament for treating a disease or disorder responsive to modulation of the activity of a protein kinase in a subject in need thereof, wherein said composition comprises (i) a reduced isoalpha acid, and (ii) a component or extract derived from Acacia; wherein a. said protein kinase is selected from the group consisting of ABL, AKT, AMPK, AURORA, BTK, CAMK, CDK, CHK, CSK, DBF2/20,EGFR, EPH/ELK/ECK, ERK/MAPKFGFR, GSK3, IGF-IR, IKKB, INSR, JAK DOM 1/2, MARK/PRKAA, MEK/STE7, MEKK/STE 11, MLK, mTOR, PAK/STE20, PDGFR, PI3K, PKC, POLO, SRC, TEC/ATK, and ZAP/SYK; b. the reduced isoalpha acid is selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydroisoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydroisocohumulone, hexahydro-isoadhumulone, and rho-isoalpha acids; and c. the component or extract derived from Acacia is derived from Acacia catechu or Acacia nilotica.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/060-329-599-751-599,Patent Application,no,0,0,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K38/43,,0,0,,,,DISCONTINUED
34,EP,A4,EP 2043622 A4,139-334-505-120-181,2010-02-24,2010,EP 07845228 A,2007-06-20,US 2007/0014414 W;;US 81506406 P,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/139-334-505-120-181,Search Report,no,6,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,7,6,042-853-584-698-551;;010-224-454-947-801;;058-133-691-269-520;;000-361-730-435-06X;;008-748-707-140-594;;013-815-574-180-274,10.1021/jf034737u;;14709013;;10.1248/bpb.26.61;;12520174;;10.1016/s0006-2952(97)00469-3;;9514086;;10.1271/bbb.59.740;;7772843;;17434926;;10.1093/carcin/bgm080;;10.1007/s10495-008-0250-5;;18726190,"MANNERING G J ET AL: ""EFFECTS OF THE HOP COMPONENT, COLUPULONE, ON THE INDUCTION OF CYTOCHROME P4503A AND THE REPLICATION OF HUMAN TUMOUR CELLS"", FOOD, NUTRITION AND CHEMICAL TOXICITY, XX, XX, 1 January 1993 (1993-01-01), pages 311 - 323, XP002031993;;CHEN WEI-JEN ET AL: ""Mechanisms of cancer chemoprevention by hop bitter acids (beer aroma) through induction of apoptosis mediated by Fas and caspase cascades"", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON; US, vol. 52, no. 1, 1 January 2004 (2004-01-01), pages 55 - 64, XP002444086, ISSN: 0021-8561;;ZHAO FENG ET AL: ""Inhibitors of nitric oxide production from hops (Humulus lupulus L.)."", BIOLOGICAL & PHARMACEUTICAL BULLETIN JAN 2003, vol. 26, no. 1, January 2003 (2003-01-01), pages 61 - 65, XP002562637, ISSN: 0918-6158;;STEPHAN T E ET AL: ""Hexahydrocolupulone and its antitumor cell proliferation activity in vitro."", BIOCHEMICAL PHARMACOLOGY 15 FEB 1998, vol. 55, no. 4, 15 February 1998 (1998-02-15), pages 505 - 514, XP002562638, ISSN: 0006-2952;;TAGASHIRA M ET AL: ""Antioxidative activity of hop bitter acids and their analogues."", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY APR 1995, vol. 59, no. 4, April 1995 (1995-04-01), pages 740 - 742, XP002562639, ISSN: 0916-8451;;LAMY VIRGINIE ET AL: ""Chemopreventive effects of lupulone, a hop beta-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis"", CARCINOGENESIS (OXFORD), vol. 28, no. 7, July 2007 (2007-07-01), pages 1575 - 1581, XP002562640, ISSN: 0143-3334;;VIRGINIE LAMY ET AL: ""Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells"", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, vol. 13, no. 10, 25 August 2008 (2008-08-25), pages 1232 - 1242, XP019599272, ISSN: 1573-675X",DISCONTINUED
35,AU,A1,AU 2007/261399 A1,197-713-098-779-889,2007-12-27,2007,AU 2007/261399 A,2007-06-20,US 81506406 P;;US 2007/0014372 W,2006-06-20,Reduced isoalpha acid based protein kinase modulation cancer treatment,,METAPROTEOMICS LLC,KONDA VEERA;;DESAI ANU;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;PACIORETTY LINDA,,https://lens.org/197-713-098-779-889,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61K35/00;;A61K36/18;;A61P37/00,,0,0,,,,DISCONTINUED
36,AU,A1,AU 2013/200576 A1,034-134-198-269-432,2013-02-21,2013,AU 2013/200576 A,2013-02-04,AU 2006/321727 A;;AU 2013/200576 A,2006-12-11,Protein kinase modulation by hops and Acacia products,"Docmnt20-4/02/2013 Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",METAPROTEONOMICS LLC,HALL AMY JENNAE;;DESAI ANU;;BLAND JEFFREY;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;BABISH JOHN G,,https://lens.org/034-134-198-269-432,Patent Application,no,0,0,1,1,0,,A61K38/43;;A61K36/00,,0,0,,,,DISCONTINUED
37,AU,A1,AU 2007/261400 A1,075-940-811-185-848,2007-12-27,2007,AU 2007/261400 A,2007-06-20,US 81506406 P;;US 2007/0014373 W,2006-06-20,Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,,METAPROTEOMICS LLC,BLAND JEFFREY;;DESAI ANU;;TRIPP MATTHEW L;;BABISH JOHN G;;HALL AMY JENNAE;;PACIORETTY LINDA;;KONDA VEERA,,https://lens.org/075-940-811-185-848,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
38,AU,A1,AU 2013/202154 A1,137-026-558-442-718,2013-05-02,2013,AU 2013/202154 A,2013-03-28,AU 2007/261338 A;;AU 2013/202154 A,2007-06-20,Beta acid based protein kinase modulation cancer treatment,"H:\SXD\Interwoven\NRPortbl\DCC\SXD\5028088_lI.doc-3/28/2013 Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops. 140 -- F I 3-Kinase 13(h) 12 a PI 3-Kinase y(h) .J PI 3-Kinase ~h ______ .. .......... .. .......... Fi . .......",METAPROTEOMICS LLC,HALL AMY JENNAE;;DESAI ANU;;BLAND JEFFREY;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;BABISH JOHN G,,https://lens.org/137-026-558-442-718,Patent Application,no,0,0,1,1,0,,A61K31/122;;A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
39,EP,A2,EP 2043621 A2,186-641-308-462-283,2009-04-08,2009,EP 07796314 A,2007-06-20,US 2007/0014450 W;;US 81506406 P,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/186-641-308-462-283,Patent Application,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
40,CA,A1,CA 2632684 A1,052-873-705-997-98X,2007-06-14,2007,CA 2632684 A,2006-12-11,US 74893105 P;;US 2006/0047196 W,2005-12-09,PROTEIN KINASE MODULATION BY HOPS AND ACACIA PRODUCTS,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;HALL AMY JENNAE;;PACIORETTY LINDA;;KONDA VEERA;;BLAND JEFFREY;;DESAI ANU,,https://lens.org/052-873-705-997-98X,Patent Application,no,0,0,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K38/43;;A61K36/00,,0,0,,,,DISCONTINUED
41,US,A1,US 2007/0281045 A1,081-743-726-824-224,2007-12-06,2007,US 63530506 A,2006-12-07,US 63530506 A;;US 68985603 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 74890705 P;;US 45023703 P;;US 42038302 P,2001-06-20,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.",TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M,METAPROTEOMICS LLC (2007-02-13),https://lens.org/081-743-726-824-224,Patent Application,yes,99,43,3,124,0,A61K36/185;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/00;;A61K36/48;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/80;;A61K36/73;;A61K36/185,A61K36/73;;A61K36/00;;A61K36/18;;A61K36/31,424/765;;424/725;;424/769,0,0,,,,EXPIRED
42,WO,A3,WO 2007/149503 A3,169-886-790-158-376,2008-05-02,2008,US 2007/0014412 W,2007-06-20,US 81506406 P,2006-06-20,XANTHOHUMOL AND TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/169-886-790-158-376,Search Report,yes,1,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/352;;A61K31/122,,2,1,000-924-641-946-825,12481418,"""REMINGTON'S PHARMACEUTICAL SCIENCES, Chapter 75"", vol. 15TH ED., 1975, MACK PUBLISHING CO., pages: 1365 - 1367;;GERHAUSER ET AL.: ""Cancer Chemopreventive Activity of Xanthohumol, a Natural Product from Hop"", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 11, pages 959 - 969",PENDING
43,WO,A3,WO 2007/149482 A3,177-857-611-744-968,2008-05-08,2008,US 2007/0014374 W,2007-06-20,US 81506406 P,2006-06-20,XANTHOHUMOL BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/177-857-611-744-968,Search Report,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/35;;A61K31/12,,2,1,000-924-641-946-825,12481418,"GERHAUSER ET AL.: ""Cancer Chemopreventive Activity of Xanthohumol, a Natural Product from Hop"", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 11, pages 959 - 969;;""Remington's Pharmaceutical Sciences, Chapter 75"", vol. 15TH ED., 1975, MACK PUBLISHING CO., pages: 1365 - 1367",PENDING
44,EP,A2,EP 2046355 A2,187-700-038-562-922,2009-04-15,2009,EP 07809708 A,2007-06-20,US 2007/0014372 W;;US 81506406 P,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/187-700-038-562-922,Patent Application,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
45,KR,A,KR 20090023721 A,001-750-362-819-590,2009-03-05,2009,KR 20097001249 A,2009-01-20,US 81506406 P,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/001-750-362-819-590,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122;;A61P35/00,,0,0,,,,DISCONTINUED
46,WO,A2,WO 2007/149504 A2,111-204-087-725-652,2007-12-27,2007,US 2007/0014413 W,2007-06-20,US 81506406 P,2006-06-20,ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/111-204-087-725-652,Patent Application,yes,0,3,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
47,WO,A2,WO 2007/149503 A2,096-582-966-697-842,2007-12-27,2007,US 2007/0014412 W,2007-06-20,US 81506406 P,2006-06-20,XANTHOHUMOL AND TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/096-582-966-697-842,Patent Application,yes,0,7,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
48,WO,A3,WO 2007/149504 A3,180-240-626-704-975,2008-03-06,2008,US 2007/0014413 W,2007-06-20,US 81506406 P,2006-06-20,ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/180-240-626-704-975,Search Report,yes,2,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/33,,0,0,,,,PENDING
49,WO,A3,WO 2007/149523 A3,174-450-362-329-574,2008-09-04,2008,US 2007/0014450 W,2007-06-20,US 81506406 P,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/174-450-362-329-574,Search Report,yes,1,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,PENDING
50,EP,A4,EP 2046353 A4,196-778-674-464-529,2010-01-27,2010,EP 07809709 A,2007-06-20,US 2007/0014373 W;;US 81506406 P,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/196-778-674-464-529,Search Report,no,3,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,2,1,003-610-553-803-08X,10.1590/s0100-40422000000100019,"DATABASE WPI Week 19783, Derwent World Patents Index; AN 1978-05666A, XP002561343;;DE KEUKELEIRE D: ""Fundamentals of beer and hop chemistry"", QUÍMICA NOVA, vol. 23, no. 1, 2000, pages 108 - 112, XP002561344",DISCONTINUED
51,CA,A1,CA 2655047 A1,088-492-408-027-343,2007-12-27,2007,CA 2655047 A,2007-06-20,US 81506406 P;;US 2007/0014414 W,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC,KONDA VEERA;;PACIORETTY LINDA;;BABISH JOHN G;;TRIPP MATTHEW L;;DESAI ANU;;BLAND JEFFREY;;HALL AMY JENNAE,,https://lens.org/088-492-408-027-343,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
52,AU,A1,AU 2006/321727 A1,175-587-100-400-055,2007-06-14,2007,AU 2006/321727 A,2006-12-11,US 74893105 P;;US 2006/0047196 W,2005-12-09,Protein kinase modulation by hops and Acacia products,,METAPROTEOMICS LLC,DESAI ANU;;BLAND JEFFREY;;KONDA VEERA;;TRIPP MATTHEW L;;HALL AMY JENNAE;;PACIORETTY LINDA;;BABISH JOHN G,,https://lens.org/175-587-100-400-055,Patent Application,no,0,0,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K38/43;;A61K36/00,,0,0,,,,DISCONTINUED
53,CA,A1,CA 2655059 A1,001-884-526-194-325,2007-12-27,2007,CA 2655059 A,2007-06-20,US 81506406 P;;US 2007/0014450 W,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-is oalpha acids, commonly found in hops.",METAPROTEOMICS LLC,PACIORETTY LINDA;;KONDA VEERA;;BABISH JOHN G;;DESAI ANU;;HALL AMY JENNAE;;TRIPP MATTHEW L;;BLAND JEFFREY,,https://lens.org/001-884-526-194-325,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
54,KR,A,KR 20090026191 A,077-258-006-298-621,2009-03-11,2009,KR 20097001251 A,2009-01-20,US 81506406 P,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/077-258-006-298-621,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/12;;A61P35/00,,0,0,,,,DISCONTINUED
55,WO,A2,WO 2007/149481 A2,112-948-243-110-683,2007-12-27,2007,US 2007/0014373 W,2007-06-20,US 81506406 P,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/112-948-243-110-683,Patent Application,yes,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
56,WO,A2,WO 2007/149482 A2,033-690-891-156-138,2007-12-27,2007,US 2007/0014374 W,2007-06-20,US 81506406 P,2006-06-20,XANTHOHUMOL BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/033-690-891-156-138,Patent Application,yes,0,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,0,0,,,,PENDING
57,EP,A2,EP 1976552 A2,031-218-199-085-490,2008-10-08,2008,EP 06839296 A,2006-12-11,US 2006/0047196 W;;US 74893105 P,2005-12-09,PROTEIN KINASE MODULATION BY HOPS AND ACACIA PRODUCTS,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/031-218-199-085-490,Patent Application,yes,0,0,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K38/43;;A61K36/00,,0,0,,,,DISCONTINUED
58,WO,A2,WO 2007/149523 A2,108-479-738-553-044,2007-12-27,2007,US 2007/0014450 W,2007-06-20,US 81506406 P,2006-06-20,HEXAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/108-479-738-553-044,Patent Application,yes,2,1,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,1,0,,,See also references of EP 2043621A4,PENDING
59,CA,A1,CA 2654964 A1,120-465-177-480-451,2007-12-27,2007,CA 2654964 A,2007-06-20,US 81506406 P;;US 2007/0014372 W,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCERTREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoa lpha acids, commonly found in hops.",METAPROTEOMICS LLC,PACIORETTY LINDA;;HALL AMY JENNAE;;KONDA VEERA;;DESAI ANU;;BABISH JOHN G;;BLAND JEFFREY;;TRIPP MATTHEW L,,https://lens.org/120-465-177-480-451,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/18;;A61K35/00,,0,0,,,,DISCONTINUED
60,EP,A4,EP 1976552 A4,190-106-237-977-633,2009-09-16,2009,EP 06839296 A,2006-12-11,US 2006/0047196 W;;US 74893105 P,2005-12-09,PROTEIN KINASE MODULATION BY HOPS AND ACACIA PRODUCTS,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/190-106-237-977-633,Search Report,no,1,0,10,23,0,A61K31/12;;A61K36/185;;A61K36/48;;A61P25/00;;A61P27/02;;A61P3/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;A61P9/10;;A61P3/10;;A61K36/185;;A61K36/48;;A61K31/12,A61K38/43;;A61K36/00,,4,4,000-924-641-946-825;;022-004-130-053-829;;031-616-827-104-845;;035-312-978-389-879,12481418;;15953717;;10.1016/j.ejca.2005.04.012;;16261517;;10.1002/ptr.1709;;15796161,"GERHAUSER CLARISSA ET AL: ""Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop"", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 11, 1 September 2002 (2002-09-01), pages 959 - 969, XP002473942, ISSN: 1535-7163;;GERHAUSER ET AL: ""Beer constituents as potential cancer chemopreventive agents"", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 41, no. 13, 1 September 2005 (2005-09-01), pages 1941 - 1954, XP025298109, ISSN: 0959-8049, [retrieved on 20050901];;LUKACZER DANIEL ET AL: ""A pilot trial evaluating Meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia"", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 19, no. 10, 1 October 2005 (2005-10-01), pages 864 - 869, XP002501482, ISSN: 0951-418X;;VANHOECKE BARBARA W ET AL: ""A safety study of oral tangeretin and xanthohumol administration to laboratory mice."", IN VIVO (ATHENS, GREECE) 2005 JAN-FEB, vol. 19, no. 1, January 2005 (2005-01-01), pages 103 - 107, XP009121181, ISSN: 0258-851X",DISCONTINUED
61,US,A1,US 2013/0064913 A1,038-120-266-145-924,2013-03-14,2013,US 201213486505 A,2012-06-01,US 201213486505 A;;US 63530506 A;;US 68985603 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 74890705 P;;US 45023703 P;;US 42038302 P,2001-06-20,ANTI-INFLAMMATORY BOTANICAL PRODUCTS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES,"Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.",TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M;;METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M,METAPROTEOMICS LLC (2007-02-13),https://lens.org/038-120-266-145-924,Patent Application,yes,0,1,3,124,0,A61K36/185;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/00;;A61K36/48;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/80;;A61K36/73;;A61K36/185,A61K36/48;;A61K31/12;;A61K31/122;;A61K31/353;;A61P3/00;;C07C49/794;;C07C49/84;;C07D311/32,424/757;;514/685;;514/690;;514/456;;549/403;;568/334;;568/379,1,1,097-429-694-618-009,10.1016/s0306-3623(96)00413-2;;9251908,"Shah et al., Gen. Pharmac. , vol. 29, no. 2, 251-255, 1997.",DISCONTINUED
62,EP,A2,EP 2043622 A2,043-249-451-749-656,2009-04-08,2009,EP 07845228 A,2007-06-20,US 2007/0014414 W;;US 81506406 P,2006-06-20,BETA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/043-249-451-749-656,Patent Application,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
63,CA,A1,CA 2655043 A1,117-546-469-830-94X,2007-12-27,2007,CA 2655043 A,2007-06-20,US 81506406 P;;US 2007/0014373 W,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-i soalpha acids, commonly found in hops.",METAPROTEOMICS LLC,BABISH JOHN G;;BLAND JEFFREY;;TRIPP MATTHEW L;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/117-546-469-830-94X,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
64,AU,A1,AU 2007/261356 A1,150-516-004-823-693,2007-12-27,2007,AU 2007/261356 A,2007-06-20,US 81506406 P;;US 2007/0014450 W,2006-06-20,Hexahydro-isoalpha acid based protein kinase modulation cancer treatment,,METAPROTEOMICS LLC,PACIORETTY LINDA;;TRIPP MATTHEW L;;HALL AMY JENNAE;;DESAI ANU;;KONDA VEERA;;BABISH JOHN G;;BLAND JEFFREY,,https://lens.org/150-516-004-823-693,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122;;A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
65,EP,A4,EP 2046355 A4,136-364-747-429-171,2010-02-03,2010,EP 07809708 A,2007-06-20,US 2007/0014372 W;;US 81506406 P,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/136-364-747-429-171,Search Report,no,3,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,2,1,003-610-553-803-08X,10.1590/s0100-40422000000100019,"DATABASE WPI Week 19783, Derwent World Patents Index; AN 1978-05666A, XP002561343;;DE KEUKELEIRE D: ""Fundamentals of beer and hop chemistry"", QUÍMICA NOVA, vol. 23, no. 1, 2000, pages 108 - 112, XP002561344",DISCONTINUED
66,WO,A3,WO 2007/149480 A3,177-479-439-392-44X,2008-07-10,2008,US 2007/0014372 W,2007-06-20,US 81506406 P,2006-06-20,REDUCED ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/177-479-439-392-44X,Search Report,yes,2,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K35/00;;A61K36/18,,1,1,025-703-982-562-115,pmc126868;;12225582;;10.1186/gb-2002-3-9-research0043,"KOSTICH M. ET AL: ""Human members of the eukaryotic protein kinase family"", GENOME BIOLOGY, vol. 3, no. 9, 2002, pages 0043.1 - 0043.12, XP021021160",PENDING
67,WO,A2,WO 2007/067812 A2,050-611-631-878-335,2007-06-14,2007,US 2006/0047196 W,2006-12-11,US 74893105 P,2005-12-09,PROTEIN KINASE MODULATION BY HOPS AND ACACIA PRODUCTS,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/050-611-631-878-335,Patent Application,yes,0,11,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K36/48;;A61K31/12;;A61K36/185,,1,0,,,See references of EP 1976552A4,PENDING
68,WO,A3,WO 2007/149481 A3,060-175-293-207-954,2008-11-27,2008,US 2007/0014373 W,2007-06-20,US 81506406 P,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/060-175-293-207-954,Search Report,yes,2,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61P37/00;;A61K36/00,,1,0,,,"KOSTICH M. ET AL.: ""Human members of the eukaryotic protein kinase family"", GENOME BIOLOGY, vol. 3, no. 9, 2002, pages 1 - 12, XP021021160",PENDING
69,EP,A2,EP 2046353 A2,074-266-437-863-195,2009-04-15,2009,EP 07809709 A,2007-06-20,US 2007/0014373 W;;US 81506406 P,2006-06-20,TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/074-266-437-863-195,Patent Application,yes,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122,,0,0,,,,DISCONTINUED
70,US,B2,US 8206753 B2,071-282-623-482-768,2012-06-26,2012,US 63530506 A,2006-12-07,US 63530506 A;;US 68985603 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 74890705 P;;US 45023703 P;;US 42038302 P,2001-06-20,Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes,"Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.",TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M;;METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M,METAPROTEOMICS LLC (2007-02-13),https://lens.org/071-282-623-482-768,Granted Patent,yes,103,6,3,124,0,A61K36/185;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/48;;A61K36/73;;A61K36/80;;A61P3/00;;A61K36/48;;A61K36/23;;A61K36/282;;A61K36/31;;A61K36/80;;A61K36/73;;A61K36/185,A01N65/00,424/725,99,46,115-121-723-074-734;;026-843-848-301-062;;042-704-235-643-115;;179-560-386-136-784;;050-747-009-682-300;;043-462-266-695-978;;109-097-981-177-440;;025-984-992-116-892;;133-000-470-545-834;;029-986-877-615-703;;069-579-068-680-540;;121-933-354-584-317;;010-562-983-298-60X;;054-037-720-710-210;;158-972-767-279-905;;106-147-087-364-667;;019-055-431-192-875;;042-853-584-698-551;;001-112-451-304-234;;102-071-695-047-127;;012-367-520-556-325;;029-494-060-881-125;;130-756-630-393-421;;045-841-689-084-370;;156-932-900-252-703;;003-610-553-803-08X;;013-295-339-616-449;;009-466-287-914-610;;000-924-641-946-825;;022-004-130-053-829;;001-800-697-473-969;;072-193-032-885-129;;020-185-497-987-452;;022-567-255-006-363;;051-229-458-430-21X;;063-629-678-241-339;;025-614-886-893-075;;050-601-377-553-842;;018-887-607-977-111;;013-815-574-180-274;;008-748-707-140-594;;031-124-211-471-152;;031-616-827-104-845;;024-794-103-749-654;;051-502-421-113-581;;004-667-040-260-44X,10.3136/fstr.10.290;;10350364;;10.1016/s0378-8741(98)00141-x;;11666119;;10.1177/000331970105202s06;;15686403;;10.1021/jf048615t;;10563881;;10.1021/jf980624c;;15088689;;10.1074/jbc.m403456200;;15178687;;15852044;;10.1038/sj.ijo.0802965;;10.1001/jama.281.21.2005;;10359389;;3155137;;18423656;;10.1016/j.chroma.2008.03.084;;14738407;;12960000;;10.1210/en.2003-0739;;12765980;;10.1373/49.6.861;;10.1021/ja01148a512;;5029117;;12932896;;10.1016/s0223-5234(03)00115-6;;10.1021/jf034737u;;14709013;;7227366;;10.1111/j.1432-1033.1981.tb06218.x;;6382953;;10.1016/0065-2571(84)90007-4;;10.1016/s0021-9258(17)39978-7;;893418;;10.1016/0022-5193(72)90040-9;;5039295;;10.1016/0022-5193(76)90169-7;;957690;;12120282;;10.1038/nrd773;;14563186;;10.1016/s1590-8658(03)00381-5;;10.1590/s0100-40422000000100019;;10405349;;10.1006/bbrc.1999.1012;;12202973;;10.1007/s10227-001-0137-3;;10.1177/120347540200600508;;12481418;;15953717;;10.1016/j.ejca.2005.04.012;;10594935;;10.1002/(sici)1099-1573(199912)13:8<665::aid-ptr563>3.0.co;2-t;;11316141;;10.1111/j.1572-0241.2001.03740.x;;10.1016/s0002-9270(01)02303-6;;11511570;;pmc1728453;;10.1136/gut.49.3.443;;5126221;;10.1016/s0021-9258(19)45905-x;;1899046;;151301;;9383683;;10.1359/jbmr.1997.12.11.1789;;10.1002/art.27441;;20201075;;10.1016/j.canlet.2003.09.002;;14732220;;10.1007/s10495-008-0250-5;;18726190;;17434926;;10.1093/carcin/bgm080;;10.1185/03007998209112375;;7128187;;16261517;;10.1002/ptr.1709;;8726300;;10.3109/00365529609006407;;pmc2915809;;10.1155/2010/467316;;20721358;;10.1021/np970343j;;9461646,"International Search Report for related PCT Application No. PCT/US2006/046770, dated Mar. 26, 2008, 8 pages.;;Written Opinion for related PCT Application No. PCT/US2006/046770, dated Mar. 26, 2008, 7 pages.;;Fukuchi, Y., et al. ""6-methylsulfinylhexyl isothiocyanate, an antioxidant derived from Wasabia japonica MATUM, ameliorates diabetic nephropathy in type 2 diabetic mice."" Food Science and Tech. Research, 2004, vol. 10, No. 3, pp. 290-295 (abstract).;;Shukla, et al., ""In vitro and in vivo would healing activity of asiaticoside isolated from Centella asiatica."" Journal of Ethnopharmacology. Apr. 1999, vol. 65, No. 1, pp. 1-11.;;Incandela, L. et al., ""Treatment of Diabetic Microangiopathy and Edema with Total Triterpenic Fraction of Centella asiatica: A Prospective, Placebo-Controlled Randomized Study."" Angiology. Oct. 2001, vol. 52, suppl. 2, pp. S27-S31.;;Parry, J., et al., ""Fatty Acid Composition and Antioxidant Properties of Cold-Pressed Marionberry, Boysenberry, Red Raspberry, and Blueberry Seed Oils."" Journal of Agriculture and Food Chemistry, Feb. 9, 2005, vol. 53, No. 3, pp. 566-573.;;Mallavarapu, G.R., et al,, ""Influence of Plant Growth Stage on the Essential Oil Content and Composition in Davana (Artemisia pallens wall.),"" Journal of Agricultural and Food Chemistry, Jan. 1999, vol. 47, No. 1, pp. 254-258.;;Dorababu, M., et al., ""Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experimental NIDDM rats."" Indian Journal of Experimental Biology, Apr. 2004, vol. 42, No. 4, pp. 389-397 (abstract).;;Yajima, H., et al., ""Isohumulones, Bitter Acids Derived from Hops, Activate Both Peroxisome Proliferator-activated Receptor alpha and gamma and Reduce Insulin Resistance."" The Journal of Biological Chemistry. Aug. 2004, vol. 279, No. 32, pp. 33456-33462.;;Yajima, H., et al,, ""Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents."" Intl. Journal of Obesity, Aug. 2005, vol, 29, No. 8, pp. 991-997.;;Turner, R.C., et al., Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS) Group JAMA Jun. 2, 1999, vol. 281, No. 21, pp. 2005-2012.;;Abel-salam et al., Pharmacological Research, England 47(4), pp. 311-340 (Apr. 2003).;;Albal, MV., et al., ""Clinical evaluation of berberine in mycotic infections."" Indian J. Ophthalmol 34:91-2 (1986).;;Anto, et al., ""Anti-inflammatory Activity of Natural and Synthetic Curcuminoids"", Pharmacy and Pharmacology Communications, 4(2), pp. 103-106 (1998).;;Baldermann et al., J. Chromatography A 1192(1):191-3 (May 23, 2008) (Epub Apr. 8, 2008); abstract only (1 page).;;Bermejo, et al. Rev. Esp. Enferm. Dig. 95(9): 621-624 and 625-628 (2003).;;Bolick D et al., Endocrinology 144(12), pp. 5227-5231 (Dec. 2003).;;Brown, et al. J. Chem. Soc. 545 (1959).;;Buhler et al., Antioxidant Activities of Flavanoids, 3 pages, Nov. 2000.;;Byrne, et al. J. Chem. Soc. (C):2810 (1971).;;Carroccio, et al. Clin. Chem. 49(6):861-867 (2003).;;Carson, J. Am. Chem. Soc. 73:1850-1851 (1951).;;Chandra, et al. Indian J. Medical Research 60(1):138-142 (1972).;;Charlier, et al. Eur. J. Med. Chem. 38:645-659 (2003).;;Chattopadhyay et al., Current Science, 87(1) (Jul. 10, 2004).;;Chen Wei-Jen et al., Journal of Agricultural and Food Chemistry 52(1), pp. 55-64 (Jan. 1, 2004).;;Chou et al. Eur. J. Biochem. 115:207-216 (1981).;;Chou, et al. Adv enzyme regul 22:27-55 (1983).;;Chou, et al. Eur. J. Biochem. 115:207-216 (1981).;;Chou, et al. J. Biol. Chem. 252(18):6438-6442 (1977).;;Chou, et al. J. Theor. Biol. 35:285-297 (1972).;;Chou, J. Theor. Biol. 59:253-276 (1976).;;Chou, et al., TIPS, pp. 450-454, Nov. 1983.;;Cohen, Protein Kinases-the major drug targets of the twenty-first century? Nature Reviews, 1: 309-315 (2002).;;Costa, et al. Digest. Liver Dis. 35:642-647 (2003).;;Davies, WL. Abstract-Fertiliser, Feeding Stuffs and Farm Supplies J. 11:694 (1926).;;De Keukeleire ""Fundamentals of Beer and Hop Chemistry"" Quimica Nova, 23(1) pp. 108-112 (2000).;;Ding, et al. Biochem. Biophy. Res. Comm. 261:218-223 (1999).;;European Examination Report for EP App. No. 02748188.6-1216.;;European Search Report for EP App. No. 07809709.4.;;European Search Report EP 05 723 839.6.;;European Search Report EP 10006768.;;European Search Report EP 10011254.;;European Search Report EP 10013109.;;European Search Report EP 10162893.;;European Search Report for corresponding EP Application No. 02737562.5 (4 pages).;;European Search Report for related European Application No. 02784313.5.;;Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases, Cleveland Clinic, www.clevelandclinic.org, Mar. 14, 2000.;;Extended European Search Report EP 10162893.1.;;Extended European Search Report EP 07717798.8.;;Extended European Search Report EP 07809708.6.;;Foucault et al., J. Chromatography A 808(1-2):3-22 (May 29, 1998); abstract only (3 pages).;;Friedman, et al. J. Cutan Med. Surg. 6(5):449-459 (2002).;;Gao et al., J. Food Sci. Nutr. vol. 9, pp. 240-244 (2004).;;Gerhauser et al., Molecular Cancer Therapeutics vol. 1, No. 11, pp. 959-969 (2002).;;Gerhauser, Beer Constituents as Potential Cancer Chemopreventive Agents, EP Journal of Cancer 41; 1941-1954: (2005).;;Germany, ""The Absolutely German Drink,"" contents of beer, 2004, 5 pages.;;Gilani, ""Studies on Antihypertensive and Antispasmodic Activities of Methanol Extract of Acacia nilotica Pods"", Phytotherapy Research 13: 665-669 (1999).;;Goldstein, et al. Am. J. Gastroenterol. 96(4):1019-1027 (2001).;;Halter, et al. Gut 49:443-453 (2001).;;Hamberg, et al. J. Bio. Chem. 246(22):6713-6721 (1971).;;Hariddradilepah 01, TKDL, Aug. 1, 1999, XP003024376, (3 pages).;;Huang, et al. Cancer Res. 51:813-819 (1991).;;Information on ArthroTrimTM product, downloaded from Internet Aug. 30, 2002.;;Information on ""Hops and Beer Flavours"", IOB Technical Symposium, Apr. 2001, pp. 1-9.;;Informatin on ""Zyflamend and Zyflamend PM"", downloaded from Internet Aug. 30, 2002.;;International Search Report for Corresponding PCT Application No. PCT/US05/41018; 2pp.;;International Search Report for PCT /US06/30920, Aug. 3, 2007, 3 pages.;;International Search Report for PCT/US02/19617.;;International Search Report for PCT/US04/16043.;;International Search Report for PCT/US06/47196.;;Jach, Przegl Dermatol. 65(4):379-381 (1978).;;Jafri et al., Pakistan Journal of Science, vol. 61, No. 4, pp. 220-222 (Dec. 2009).;;Kaltner, Investigation of formation of Hops Aroma and technological Measures for Products of Hops-Aromatic Beers, Technical University of Munich, 7 pp. corresponding to Kaltner, D., Technische Universitat Munchen, (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-AH31.;;Kanematsu, et al. J Bone Miner Res 12(11):1789-1796 (1997).;;Konda, et al., Arthritis & Rheumatism 62(6): 1683-1692, (2010).;;Kuo et al., Cancer Letter, 203:127-137 (2004).;;Lamy Virginie et al., Apoptosis, an Int'l Journal on Programmed Cell Death, 13(10), pp. 1232-1242 (Aug. 25, 2008).;;Lamy Virginie et al., Carcinogenesis, 28(7), pp. 1575-1581 (Jul. 2007).;;Lerman et al, FASEB Journal , Fed. of American Soc. for Experimental Biol., vol. 18, No. 4-5 (Jan. 1, 2004).;;Lopes, Curr. Med Res Opin. 8(3):145-149 (1982).;;Lukaczer et al., Phytotherapy Research, vol. 19, No. 10, pp. 864-869 (2005).;;Mannering et al., Food, Nutrition and Chemical Toxicity X(X), pp. 311-323 (Jan. 1, 1993).;;Meling, et al. Scand. J. Gastroenterol. 31:339-344 (1996).;;Minich et al., Journal of nutrition and Metabolism, vol. 2010, article ID 467316, pp. 1-11, (2010).;;Murvadyaghrtam, TKDL, Jan. 1, 2001, XP003024377 (4 pages).;;Murvadyaghrtam, TKDL, Jan. 1, 1990, XP003024379 (4 pages).;;Newark, et al., ""Beyond Aspirin"", pp. 147-151, Hohm Press (2000).;;Noreen, et al. J. Nat. Prod 61:2-7 (1998).;;Office Action issued for U.S. Appl. No. 11/667,614 mailed Apr. 16, 2010.;;Office Action issued for U.S. Appl. No. 11/667,615 mailed Mar. 16, 2010.;;Office Action issued for U.S. Appl. No. 11/701,583 mailed Feb. 8, 2008.;;Office Action issued for U.S. Appl. No. 11/701,583 mailed Jul. 6, 2009.;;Office Action issued for U.S. Appl. No. 11/701,583 mailed Nov. 26, 2008.;;Office Action issued in U.S. Appl. No. 10/464,834 on Aug. 3, 2010.;;Office Action issued in U.S. Appl. No. 10/532,388 on Mar. 26, 2010.;;Office Action issued in U.S. Appl. No. 10/532,388 on Jun. 28, 2011.;;Office Action issued in U.S. Appl. No. 10/590,301 on Aug. 19, 2010.;;Office Action issued in U.S. Appl. No. 10/590,424 on Jun. 29, 2010.",EXPIRED
71,AU,A1,AU 2007/261338 A1,084-501-290-918-285,2007-12-27,2007,AU 2007/261338 A,2007-06-20,US 81506406 P;;US 2007/0014414 W,2006-06-20,Beta acid based protein kinase modulation cancer treatment,,METAPROTEOMICS LLC,HALL AMY JENNAE;;DESAI ANU;;KONDA VEERA;;PACIORETTY LINDA;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY,,https://lens.org/084-501-290-918-285,Patent Application,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122;;A61K36/00;;A61P37/00,,0,0,,,,DISCONTINUED
72,WO,A1,WO 2007/149485 A1,124-655-617-438-875,2007-12-27,2007,US 2007/0014380 W,2007-06-20,US 81506406 P,2006-06-20,ACACIA BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on Acacia fractions, compounds, and extracts.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY;;HALL AMY JENNAE;;KONDA VEERA;;PACIORETTY LINDA;;DESAI ANU,,https://lens.org/124-655-617-438-875,Patent Application,yes,3,3,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00,,1,0,,,"DATABASE WPI Week 200578, Derwent World Patents Index; Class B04, AN 2005-761614, ACHARYA H.: ""Ayurvedic medicinal composition for treating uterus""",PENDING
73,US,A1,US 2008/0031893 A1,164-093-066-475-037,2008-02-07,2008,US 82062107 A,2007-06-20,US 82062107 A;;US 81506406 P,2006-06-20,Acacia based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on Acacia fractions, compounds, and extracts.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/164-093-066-475-037,Patent Application,yes,18,4,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/48;;A61P35/00,424/195.18;;424/757,2,0,,,"http://www.uniprot.org/uniprot/P63086 - accessed 4/2013;;Wassel (Egyptian Journal of Pharmaceutical Sciences (1992), vol. 33, no. 1-2, pp. 327-340)",DISCONTINUED
74,US,A1,US 2008/0033057 A1,141-134-562-008-693,2008-02-07,2008,US 82060807 A,2007-06-20,US 82060807 A;;US 81506406 P,2006-06-20,Hexahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/141-134-562-008-693,Patent Application,yes,99,7,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/121;;A61P35/00,514/690,0,0,,,,DISCONTINUED
75,TW,A,TW 200819120 A,108-342-577-550-143,2008-05-01,2008,TW 96122224 A,2007-06-20,US 81506406 P,2006-06-20,Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/108-342-577-550-143,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/122;;A61K31/047;;A61P35/00,,0,0,,,,PENDING
76,US,B2,US 7736677 B2,058-797-118-540-316,2010-06-15,2010,US 82056807 A,2007-06-20,US 82056807 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 48014504 A;;US 45023703 P;;US 42038302 P,2001-06-20,Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/058-797-118-540-316,Granted Patent,yes,20,11,3,124,0,A61K31/12;;A61K31/122;;A61K36/185;;A61K36/53;;A61P35/00;;A61K31/12;;A61K36/53;;A61K31/122;;A61K36/185,A01N65/00,424/725,52,40,082-857-044-481-107;;056-084-479-750-455;;008-227-583-763-402;;003-716-626-998-267;;022-907-446-340-178;;102-071-695-047-127;;039-891-123-543-871;;059-538-886-189-442;;064-023-687-827-964;;048-812-779-123-026;;000-679-944-953-68X;;130-643-811-466-094;;006-533-226-299-579;;027-711-276-991-214;;011-300-160-316-666;;025-703-982-562-115;;014-246-586-671-598;;049-987-836-527-31X;;049-931-091-627-283;;014-616-548-039-132;;093-330-122-656-40X;;114-599-370-248-482;;048-398-498-525-431;;008-688-236-785-043;;038-372-423-749-600;;080-226-667-361-116;;092-531-764-711-487;;000-782-165-862-944;;108-903-973-559-163;;016-086-886-526-862;;109-097-981-177-440;;031-531-124-995-423;;014-354-136-199-765;;027-580-801-485-719;;078-536-866-740-364;;028-032-198-644-488;;023-655-091-490-078;;032-263-754-417-634;;099-968-706-681-044;;000-924-641-946-825,15892652;;10.2174/1566524053766022;;2692037;;10.2337/diabetes.46.1.3;;8971073;;10.2337/diab.46.1.3;;10.1074/jbc.c100462200;;11533044;;11387480;;10.1126/science.292.5522.1728;;6382953;;10.1016/0065-2571(84)90007-4;;10.1056/nejm200103223441207;;11259725;;pmc2199061;;10.1084/jem.186.7.1027;;9314552;;10.1093/nar/11.5.1475;;pmc325809;;6828386;;10.1006/bbrc.2001.6307;;11798186;;8834766;;10.1007/bf00202068;;10.1038/1841296b0;;14402470;;10.1016/s0021-9258(18)42487-8;;1569106;;10.1182/blood-2002-04-1251;;12393431;;6181064;;10.1016/s0021-9258(18)33704-9;;pmc126868;;12225582;;10.1186/gb-2002-3-9-research0043;;10.1210/mend.16.5.0825;;11981038;;10.1210/me.16.5.1040;;10.1016/s0021-9150(97)00315-8;;9694545;;10.1074/jbc.m407805200;;15536084;;11334421;;10.2337/diabetes.50.5.1158;;10.1111/j.1432-1033.1983.tb07140.x;;6402364;;10586078;;15386813;;10.1002/dmrr.493;;10.1128/mcb.22.23.8101-8113.2002;;12417714;;pmc134064;;10.1080/713782132;;10.1080/ann.34.3.217.224;;12173692;;10871236;;10.1097/00075197-200005000-00007;;10.1038/70293;;10587646;;10.1016/s1471-4892(03)00078-x;;12901953;;pmc22126;;10377455;;10.1073/pnas.96.13.7563;;10.1517/13543784.13.7.743;;15212616;;10.1074/jbc.m403456200;;15178687;;8477717;;10.1111/j.1432-1033.1993.tb17781.x;;10.1074/jbc.m103241200;;11533050;;10.1210/jc.86.8.3815;;11502817;;10.1210/jcem.86.8.7741;;10418944;;10.1016/s0278-6915(99)00019-8;;15796152;;10.1021/jf050550m;;16028974;;10.1016/j.jep.2005.01.040;;15908150;;15688078;;10.1038/nrd1635;;12481418,"Arner, P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Mol Med.;5(3):333-9, (May 2005).;;Berenbaum, M. C. What is synergy? Pharmacol Rev 41(2), 93-141, (1989).;;Boden, G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46(1): 3-10, (1997).;;Cho et al., J Biol Chem 276:38345-38352 (2001).;;Cho et al., Science 292:1728-1731 (2001).;;Chou, T.C. and P. Talalay. Quantitative analysis of dose-effect relationships; the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, (1984).;;Choy EHS and Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Eng J Med. 344:907-916, 2001.;;Crowley, M. T., et al,. J. Exp. Med. 186: 1027-1039, (1997).;;Dignam, et al., Nucl Acids Res 11:1475-1489, (1983).;;Fasshauer, M., Klein, J., Neumann, S., Eszlinger, M., and Paschke, R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 290: 1084-1089, (2002).;;Hibi, M., Nakajima, K., Hirano T. IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med. 74(1):1-12, (Jan. 1996).;;Hofstee, B.H. Non-inverted versus inverted plots in enzyme kinetics. Nature 184:1296-1298, (1959).;;Hutchcroft, J. E., Harrison, M. L. & Geahlen, R. L. (1992). Association of the 72-kDa protein-tyrosine kinase Ptk72 with the B-cell antigen receptor. J. Biol. Chem. 267: 8613-8619, (1992).;;Jiang, K., et al., Blood 101, 236-244, (2003).;;Kasturi, R. and Joshi, V. C. Hormonal regulation of stearoyl coenzyme A desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells. J Biol Chem, 257: 12224-12230, (1982).;;Kostich, M., et al., Human Members of the Eukaryotic Protein Kinase Family, Genome Biology 3(9):research0043.1-0043.12, 2002.;;Li, Y. and Lazar, M. A. Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2. Mol Endocrinol, 16: 1040-1048, (2002).;;Martin, G., K. Schoonjans, et al. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 137 Suppl: S75-80, (1998).;;Moon KD, et al., Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase. J. Biol. Chem. 280, No. 2, Issue of Jan. 14, pp. 1543-1551, (2005).;;Oakes, N. D., P. G. Thalen, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50(5): 1158-65, (2001).;;Parker, P. J., Caudwell, F. B., and Cohen, P. (1983) Eur. J. Biochem. 130:227-234.;;Raeder, E. M., et al., J. Immunol. 163, 6785-6793, (1999).;;Raz, I., Eldor, R., Cernea, S., and Shafrir, E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev, 21: 3-14, (2005).;;Stolovich et al. Mol Cell Biol Dec, 8101-8113 (2002).;;Stumvoll, M. and H. U. Haring Glitazones: clinical effects and molecular mechanisms. Ann Med 34(3): 217-24, (2002).;;van der Kraan PM and van den Berg WB. Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care,3:205-211, 2000.;;Verdu et al., Nat cell Biol 1:500-505 (1999).;;Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol. Aug;3(4):426-34, (2003).;;Warner, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo- oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96, 7563-7568, (1999).;;Wong BR, et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-762, 2004.;;Yajima, H., Ikeshima, E., Shiraki, M., Kanaya, T., Fujiwara, D., Odai, H., Tsuboyama-Kasaoka, N., Ezaki, O., Oikawa, S., and Kondo, K. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J Biol Chem, 279: 33456-33462, (2004).;;Yamada, T., Taniguchi, T., Yang, C., Yasue, S., Saito, H. & Yamamura, H. Association with B-cell antigen cell antigen receptor with protein-tyrosine kinase-P72(Syk) and activation by engagement of membrane IgM. Eur. J. Biochem. 213: 455-459,(1993).;;Yamauchi, T., J. Kamon, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276(44): 41245-54, (2001).;;Yang, W. S., W. J. Lee, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86(8): 3815-9, (2001).;;International Search Report for corresponding PCT Application No. PCT/US2007/14372, 5 PP.;;Written Opinion for corresponding PCT Application No. PCT/US2007/14372, 5 PP.;;International Search Report for related PCT Application No. PCT/US2007/014373.;;Written Opinion for related PCT Application No. PCT/US2007/014373.;;Miranda et al. Antiproliferative and Cytotoxic Effects of Prenylated Flavanoids from hops (Humulus lupulus) in human cancer cell lines. Food and Chemical Toxicology, 1999, 27, pp. 271-285.;;Machine Translation of DE19939350 obtained from EPO on Sep. 4, 2008.;;Zips et al. New anticancer agents: in vitro and in vivo evaluation. In Vivo. 2005, 19, pp. 1-8.;;Wu et al., Phenolic antioxidants from the heartwood of Acacia confusa. J. Agric. Food checm. 2005, 53, pp. 5917-5921.;;Kaur, Journal of Ethnopharmacology, May 2005, vol. 99, pp. 353-360.;;Kamb, Nature Reviews: Drug Discovery 2005, vol. 4, pp. 16-165.;;www.dfa.gov/fdac/special/testtubetopatient/studies.html-accessed Sep. 2008.;;Remington's Pharmaceutical Sciences, 15th edition, Mack Publishing Co., Chapter 75, pp 1365-1367 (9175), 1975.;;Gerhauser, et al., Cancer chemopreventive Activity of Xanthohumol, a Natural Product from Hop, Molecular Cancer Therapeutics, vol. 1., No. 11, pp. 959-969, Abstract and Figs 1-5, 2002.;;International Search Report for Corresponding PCT Application No. PCT/US07/14412, 2 pp.;;Written Opinion for Corresponding PCT Application No. PCT/US07/14412, 4 pp.;;International Search Report for corresponding PCT Application No. PCT/US2007/14380, 2 PP.;;Written Opinion for corresponding PCT Application No. PCT/US2007/14380, 4 PP.;;Database Derwent ACC-No. 2005-761614 on STN. ""Ayurvedic medicinal composition for treating uterus"". Acharya, H. IN 200101228 II, Mar. 11, 2005, Derwent English Abstract.",EXPIRED
77,US,A1,US 2008/0051465 A1,110-632-604-689-974,2008-02-28,2008,US 82056807 A,2007-06-20,US 82056807 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 48014504 A;;US 45023703 P;;US 42038302 P,2001-06-20,Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/110-632-604-689-974,Patent Application,yes,16,22,3,124,0,A61K31/12;;A61K31/122;;A61K36/185;;A61K36/53;;A61P35/00;;A61K31/12;;A61K36/53;;A61K31/122;;A61K36/185,A61K31/12;;A61P35/00,514/685,0,0,,,,EXPIRED
78,US,A1,US 2008/0031982 A1,012-789-361-036-313,2008-02-07,2008,US 82060007 A,2007-06-20,US 82060007 A;;US 81506406 P,2006-06-20,Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on tetrahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/012-789-361-036-313,Patent Application,yes,16,6,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61P37/00,424/775,0,0,,,,DISCONTINUED
79,TW,A,TW 200819121 A,061-979-304-146-457,2008-05-01,2008,TW 96122225 A,2007-06-20,US 81506406 P,2006-06-20,Hexahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on hexahydro-isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/061-979-304-146-457,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/047;;A61K31/122;;A61P35/00,,0,0,,,,PENDING
80,TW,A,TW 200817023 A,044-847-185-536-653,2008-04-16,2008,TW 96122220 A,2007-06-20,US 81506406 P,2006-06-20,Xanthohumol based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/044-847-185-536-653,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/185;;A61P37/00,,0,0,,,,PENDING
81,US,A1,US 2008/0051466 A1,083-837-918-486-08X,2008-02-28,2008,US 82060707 A,2007-06-20,US 82060707 A;;US 81506406 P,2006-06-20,Isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/083-837-918-486-08X,Patent Application,yes,99,2,1,58,0,A61K31/12;;A61P35/00;;A61K31/12,A61K31/12;;A61P35/00,514/690,0,0,,,,DISCONTINUED
82,US,A1,US 2011/0021637 A1,003-523-018-955-975,2011-01-27,2011,US 75482010 A,2010-04-06,US 75482010 A;;US 82056807 A;;US 46441003 A;;US 40029303 A;;US 40128303 A;;US 46483403 A;;US 88572101 A;;US 48014504 A;;US 45023703 P;;US 42038302 P,2001-06-20,XANTHOHUMOL AND TETRAHYDRO-ISOALPHA ACID BASED PROTEIN KINASE MODULATION CANCER TREATMENT,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/003-523-018-955-975,Patent Application,yes,3,5,3,124,0,A61K31/12;;A61K31/122;;A61K36/185;;A61K36/53;;A61P35/00;;A61K31/12;;A61K36/53;;A61K31/122;;A61K36/185,A61K31/12;;A61P35/00,514/679,0,0,,,,DISCONTINUED
83,US,A1,US 2008/0026088 A1,192-214-902-021-430,2008-01-31,2008,US 82065307 A,2007-06-20,US 82065307 A;;US 81506406 P,2006-06-20,Reduced isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/192-214-902-021-430,Patent Application,yes,99,10,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/18;;A61P35/00,424/778,1,1,003-610-553-803-08X,10.1590/s0100-40422000000100019,Keukeleire FUNDAMENTALS OF BEER AND HOP CHEMISTRY; QUÍMICA NOVA 23(1) (2000) pp. 108-112.,DISCONTINUED
84,TW,A,TW 200816982 A,016-000-164-568-331,2008-04-16,2008,TW 96122216 A,2007-06-20,US 81506406 P,2006-06-20,Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, or tetrahydro-isoalpha acids commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/016-000-164-568-331,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/12;;A61K31/122;;A61K36/185;;A61P37/00,,0,0,,,,PENDING
85,TW,A,TW 200816980 A,116-220-321-871-538,2008-04-16,2008,TW 96122223 A,2007-06-20,US 81506406 P,2006-06-20,Beta acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/116-220-321-871-538,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61K31/045;;A61P35/00,,0,0,,,,PENDING
86,TW,A,TW 200817022 A,030-791-594-718-636,2008-04-16,2008,TW 96122217 A,2007-06-20,US 81506406 P,2006-06-20,Acacia based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on Acacia fractions, compounds, and extracts.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/030-791-594-718-636,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/185;;A61P37/00,,0,0,,,,PENDING
87,TW,A,TW 200817026 A,120-382-506-329-506,2008-04-16,2008,TW 96122227 A,2007-06-20,US 81506406 P,2006-06-20,Reduced isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/120-382-506-329-506,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/60;;A61K36/48;;A61P35/00,,0,0,,,,PENDING
88,TW,A,TW 200817027 A,126-895-176-005-358,2008-04-16,2008,TW 96122231 A,2007-06-20,US 81506406 P,2006-06-20,Isoalpha acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on isoalpha acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,,https://lens.org/126-895-176-005-358,Patent of Addition,no,0,0,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/605;;A61K31/047;;A61P35/00,,0,0,,,,PENDING
89,US,A1,US 2008/0033056 A1,096-604-116-981-980,2008-02-07,2008,US 82074707 A,2007-06-20,US 82074707 A;;US 81506406 P,2006-06-20,Xanthohumol based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on xanthohumol or isoxantohumol, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/096-604-116-981-980,Patent Application,yes,17,3,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K31/12;;A61P35/00,514/685,0,0,,,,DISCONTINUED
90,US,A1,US 2008/0031894 A1,110-136-065-148-323,2008-02-07,2008,US 82075507 A,2007-06-20,US 82075507 A;;US 81506406 P,2006-06-20,Beta acid based protein kinase modulation cancer treatment,"Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on beta acids, commonly found in hops.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;HALL AMY;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-08-24),https://lens.org/110-136-065-148-323,Patent Application,yes,18,6,57,58,0,A61K36/185;;A61P1/04;;A61P1/16;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/14;;A61P19/02;;A61P25/00;;A61P27/16;;A61P29/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/06;;A61P3/10;;A61K31/12;;A61K36/185,A61K36/00;;A61P35/00,424/195.18;;424/778,0,0,,,,DISCONTINUED
91,US,A1,US 2007/0154576 A1,017-226-294-665-920,2007-07-05,2007,US 63686706 A,2006-12-11,US 63686706 A;;US 74893105 P,2005-12-09,Protein kinase modulation by hops and Acacia products,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-01-31),https://lens.org/017-226-294-665-920,Patent Application,yes,71,30,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K36/185;;A61K31/12;;A61K36/48,424/757;;424/778;;514/690,0,0,,,,DISCONTINUED
92,US,A1,US 2008/0031986 A1,124-125-906-267-656,2008-02-07,2008,US 82393407 A,2007-06-29,US 82393407 A;;US 63686706 A;;US 74893105 P,2005-12-09,Protein kinase modulation by hops and acacia products,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;PACIORETTY LINDA M;;DESAI ANU,METAPROTEOMICS LLC (2007-01-31),https://lens.org/124-125-906-267-656,Patent Application,yes,100,21,10,23,0,A61K36/185;;A61K36/185;;A61K31/12;;A61K31/12;;A61K36/48;;A61K36/48;;A61P3/00;;A61P3/10;;A61P9/10;;A61P25/00;;A61P27/02;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,A61K36/48;;A61K31/122;;A61K31/352,424/778;;424/725;;514/456;;514/690,0,0,,,,DISCONTINUED
93,US,A1,US 2007/0042063 A1,196-282-271-917-475,2007-02-22,2007,US 50139306 A,2006-08-09,US 50139306 A;;US 70698405 P;;US 74893105 P,2005-08-09,Protein kinase modulation by hops and acacia products,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;DESAI ANU,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;DESAI ANU,METAPROTEOMICS LLC (2006-10-23),https://lens.org/196-282-271-917-475,Patent Application,yes,99,14,13,23,0,A61K31/12;;A61K36/185;;A61K36/48;;A61K45/06;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;A61P3/10;;A61K36/185;;A61K36/48;;A61K45/06;;A61K31/12,A61K36/48;;A61K31/12;;A61K36/185,424/757;;424/778;;514/690,0,0,,,,ACTIVE
94,US,B2,US 8263139 B2,005-465-004-436-015,2012-09-11,2012,US 50139306 A,2006-08-09,US 50139306 A;;US 70698405 P;;US 74893105 P,2005-08-09,Protein kinase modulation by hops and Acacia products,"Botanical compounds to modulate kinase activity are disclosed. The compounds and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compositions contain at least one fraction isolated or derived from hops or Acacia.",TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;DESAI ANU;;METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;PACIORETTY LINDA M;;BLAND JEFFREY S;;HALL AMY J;;KONDA VEERA;;DESAI ANU,METAPROTEOMICS LLC (2006-10-23),https://lens.org/005-465-004-436-015,Granted Patent,yes,103,2,13,23,0,A61K31/12;;A61K36/185;;A61K36/48;;A61K45/06;;A61P25/00;;A61P27/02;;A61P29/00;;A61P3/00;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;A61P3/10;;A61K36/185;;A61K36/48;;A61K45/06;;A61K31/12,A61K36/00;;A61K36/48,424/725;;424/779,107,85,099-841-445-254-248;;009-369-837-214-383;;031-858-345-391-978;;144-320-100-400-664;;082-857-044-481-107;;056-084-479-750-455;;008-227-583-763-402;;003-716-626-998-267;;022-907-446-340-178;;102-071-695-047-127;;039-891-123-543-871;;059-538-886-189-442;;064-023-687-827-964;;048-812-779-123-026;;000-679-944-953-68X;;130-643-811-466-094;;006-533-226-299-579;;027-711-276-991-214;;011-300-160-316-666;;014-246-586-671-598;;049-987-836-527-31X;;049-931-091-627-283;;014-616-548-039-132;;093-330-122-656-40X;;114-599-370-248-482;;048-398-498-525-431;;038-372-423-749-600;;080-226-667-361-116;;092-531-764-711-487;;000-782-165-862-944;;108-903-973-559-163;;016-086-886-526-862;;109-097-981-177-440;;031-531-124-995-423;;014-354-136-199-765;;027-580-801-485-719;;121-933-354-584-317;;054-037-720-710-210;;158-972-767-279-905;;106-147-087-364-667;;019-055-431-192-875;;001-112-451-304-234;;102-071-695-047-127;;012-367-520-556-325;;029-494-060-881-125;;042-588-311-955-44X;;130-756-630-393-421;;045-841-689-084-370;;156-932-900-252-703;;013-295-339-616-449;;009-466-287-914-610;;022-004-130-053-829;;001-800-697-473-969;;072-193-032-885-129;;020-185-497-987-452;;022-567-255-006-363;;051-229-458-430-21X;;063-629-678-241-339;;025-614-886-893-075;;031-124-211-471-152;;024-794-103-749-654;;004-667-040-260-44X;;007-954-977-088-328;;075-846-751-352-382;;029-078-235-344-098;;072-840-419-745-049;;064-650-971-153-058;;143-527-150-836-53X;;044-614-739-037-390;;065-589-406-540-887;;045-262-692-290-996;;058-237-018-131-886;;064-779-664-029-900;;111-276-145-963-302;;082-140-959-219-440;;000-361-730-435-06X;;022-729-620-008-375;;067-863-630-064-207;;068-953-111-479-617;;047-896-539-999-138;;108-903-973-559-163;;095-111-719-225-71X;;059-755-683-902-886;;091-619-916-275-398;;076-934-814-889-125,7842467;;10.1093/cvr/28.11.1713;;17641284;;10.1677/joe-06-0121;;16513829;;10.1210/en.2005-1433;;10.3746/jfn.2004.9.3.240;;15892652;;10.2174/1566524053766022;;2692037;;10.2337/diabetes.46.1.3;;8971073;;10.2337/diab.46.1.3;;10.1074/jbc.c100462200;;11533044;;11387480;;10.1126/science.292.5522.1728;;6382953;;10.1016/0065-2571(84)90007-4;;10.1056/nejm200103223441207;;11259725;;pmc2199061;;10.1084/jem.186.7.1027;;9314552;;10.1093/nar/11.5.1475;;pmc325809;;6828386;;10.1006/bbrc.2001.6307;;11798186;;8834766;;10.1007/bf00202068;;10.1038/1841296b0;;14402470;;10.1016/s0021-9258(18)42487-8;;1569106;;10.1182/blood-2002-04-1251;;12393431;;6181064;;10.1016/s0021-9258(18)33704-9;;10.1210/mend.16.5.0825;;11981038;;10.1210/me.16.5.1040;;10.1016/s0021-9150(97)00315-8;;9694545;;10.1074/jbc.m407805200;;15536084;;11334421;;10.2337/diabetes.50.5.1158;;10.1111/j.1432-1033.1983.tb07140.x;;6402364;;10586078;;15386813;;10.1002/dmrr.493;;10.1080/713782132;;10.1080/ann.34.3.217.224;;12173692;;10871236;;10.1097/00075197-200005000-00007;;10.1038/70293;;10587646;;10.1016/s1471-4892(03)00078-x;;12901953;;pmc22126;;10377455;;10.1073/pnas.96.13.7563;;10.1517/13543784.13.7.743;;15212616;;10.1074/jbc.m403456200;;15178687;;8477717;;10.1111/j.1432-1033.1993.tb17781.x;;10.1074/jbc.m103241200;;11533050;;10.1210/jc.86.8.3815;;11502817;;10.1210/jcem.86.8.7741;;14738407;;12765980;;10.1373/49.6.861;;10.1021/ja01148a512;;5029117;;12932896;;10.1016/s0223-5234(03)00115-6;;7227366;;10.1111/j.1432-1033.1981.tb06218.x;;6382953;;10.1016/0065-2571(84)90007-4;;10.1016/s0021-9258(17)39978-7;;893418;;10.1016/0022-5193(72)90040-9;;5039295;;10.1016/0165-6147(83)90490-x;;10.1016/0022-5193(76)90169-7;;957690;;12120282;;10.1038/nrd773;;14563186;;10.1016/s1590-8658(03)00381-5;;10405349;;10.1006/bbrc.1999.1012;;12202973;;10.1007/s10227-001-0137-3;;10.1177/120347540200600508;;15953717;;10.1016/j.ejca.2005.04.012;;10594935;;10.1002/(sici)1099-1573(199912)13:8<665::aid-ptr563>3.0.co;2-t;;11316141;;10.1111/j.1572-0241.2001.03740.x;;10.1016/s0002-9270(01)02303-6;;11511570;;pmc1728453;;10.1136/gut.49.3.443;;5126221;;10.1016/s0021-9258(19)45905-x;;1899046;;151301;;9383683;;10.1359/jbmr.1997.12.11.1789;;10.1185/03007998209112375;;7128187;;8726300;;10.3109/00365529609006407;;10.1021/np970343j;;9461646;;2617166;;1194716;;10.1111/1523-1747.ep12610281;;12795745;;10.1046/j.1440-1746.2003.03014.x;;10.1021/np980088i;;9784154;;10.1016/s1590-8658(03)00375-x;;14563180;;10.1046/j.1365-2133.2003.05536.x;;14510979;;10.1136/gut.48.3.339;;pmc1760142;;11171823;;11708802;;10.1006/bbrc.2001.5934;;11522616;;14748750;;10.1111/j.1472-8206.2004.00203.x;;10.1094/asbcj-56-0052;;10811116;;9485026;;10.1271/bbb.59.740;;7772843;;12783101;;10.1358/dot.2001.37.2.614846;;pmc1727647;;10446103;;10.1136/gut.45.3.362;;10.1271/bbb.61.158;;9028043;;10.1016/j.chroma.2004.02.038;;15117074;;pmc22126;;10377455;;10.1073/pnas.96.13.7563;;10.1016/s0014-5793(99)01727-5;;10631313;;10.1248/bpb.26.753;;12808281;;12546701;;10.1042/bst0310275;;10.1142/s0192415x96000323;;8982438,"El-Toumy et al., Polyphenols from Acacia nilotica leaves and evaluation of antihyperglycemic effect of aqueous extract, Bulletin of the Faculty of Pharmacy (2004), 42 (2), 317-325.;;Kiosseva et al, Mitogen-activated protein kinase signaling abnormalities in the cerebellum in major psychiatric disorders, Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) vol. 2003, pp. Abstract No. 447.7.;;Bohm et al, cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium, Cardiovascular research, (Nov. 1994) vol. 28, No. 11, pp. 1713-1719.;;Fleming et al, The mitogen-activated protein kinase pathway tonically inhibits both basal and IGF-I-stimulated IGF-binding protein-5 production in mammary epithelial cells, The Journal of endocrinology, (Aug. 2007) vol. 194, No. 2, pp. 349-359.;;Yang et al, Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis, Endocrinology, (Jun. 2006) vol. 147, No. 6, pp. 2728-2736.;;Gao et al, Hypoglycemic properties of polysaccharides extracted from Ganoderma lucidum in alloxan-induced diabetic rats, Journal of Food Science and Nutrition (2004), 9(3), 240-244.;;Jafri et al, Effect of Momordica charantia (Karela) in alloxan induced diabetic rats, Pakistan Journal of Science, (2009) vol. 61, No. 4, pp. 220-222.;;Wassel et al, Phytochemical examination and biological studies of Acacia nilotica L. Willd and Acacia farnesiana L. Willd growing in Egypt, Egyptian Journal of Pharmaceutical Sciences, (1992) vol. 33, No. 1-2, pp. 327-340.;;Arner, P., Insulin Resistance in Type 2 Diabetes-Role of the Adipokines. Curr. Mol. Med.; 5(3):333-339, (May 2005).;;Berenbaum, M.C., What is Synergy?: Pharmacol Rev; 41(2):93-141 (1989).;;Boden, G., Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM. Diabetes 46(1): 3-10, (1997).;;Cho et al., Akt1/PKBa is Required for Normal Growth but Dispensable for Maintenance Glucose Homeostasis in Mice, J Biol Chem 276:38349-38352 (2001).;;Cho et al., Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBbeta), Science 292:1728-1731 (2001).;;Chou, T.C., et al., Quantitative Analysis of Dose-effect Relationships; The Combined Effects of Multiple Drugs or Enzyme Inhibitors; Adv Enzyme Regul 22:27-55, (1984).;;Choy, et al., Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis; New England Jour. Med. 344:pp. 907-916, (2001).;;Crowley, et al., A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fcgamma Receptors on Macrophages; J. Exp. Med. 186:1027-1039, (1997).;;Dignam, et al., Accurate Transcription Initiation by RNA Polymerase II in a Soluble Extract From Isolated Mammalian Nuclei; Nucl Acids Res 11:1475-1489, (1983).;;Fasshauer, M., et al., Hormonal Regulation of Adiponectin Gene Expression in 3T3-L1 Adipocytes; Biochem Biophys Res Commun, 290:1084-1089, (2002).;;Hibi, M., et al., IL-6 Cytokine Family and Signal Transduction: A Model of the Cytokine System. J Mol Med. 74(1):1-12, (Jan. 1996).;;Hofstee, B.H., Non-inverted Versus Inverted Plots in Enzyme Kinetics; Nature 184:1296-1298, (1959).;;Hutchcroft, J. E., et al., Association of the 72-kDa Protein-tyrosine Kinase Ptk72 with the B-cell Antigen Receptor; J. Biol. Chem. 267:8613-8619, (1992).;;Jiang, K., et al., Regulation of Akt-dependent Cell Survival by Syk and Rac; Blood 101, pp. 236-244, (2003).;;Kasturi, R., et al., Hormonal Regulation of Stearoyl Coenzyme a Desaturase Activity and Lipogenesis During Adipose Conversion of 3T3-L1 Cells; J Biol Chem, 257:12224-12230, 1982.;;Li, Y., et al., Differential Gene Regulation by PPARgamma Agonist and Constitutively Active PPARgamma2; Mol. Endocrinol., 16:1040-1048, (2002).;;Martin, G., et al. PPARgamma Activators Improve Glucose Homeostasis by Stimulating Fatty Acid Uptake in the Adipocytes; Atherosclerosis 137 Suppl:S75-S80, (1998).;;Moon KD, et al., Molecular Basis for a Direct Interaction between the Syk Protein-tyrosine Kinase and Phosphoinositide 3-Kinase; J. Biol. Chem. 280, No. 2, Issue of Jan. 14, pp. 1543-1551, (2005).;;Oakes, N. D., et al., Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability; Diabetes 50(5):1158-1165, (2001).;;Parker, P. J., et al., Glycogen Synthase from Rabbit Skeletal Muscle; Effect of Insulin on the State of Phosphorylation of the Seven Phosphoserine Residues in vivo; (1983) Eur. J. Biochem. 130:227-234.;;Raeder, E. M., et al., Syk Activation Initiates Downstream Signaling Events During Human Polymorphonuclear Leukocyte Phagocytosis, J. Immunol. 163: 6785-6793, (1999).;;Raz, I, et al.; Diabetes: insulin resistance and derangements in lipid metabolism. Cure Through intervention in fat transport and storage; Diabetes Metab. Res. Rev.; 21: 3-14 (2005).;;Stumvoll, M., et al., Glitazones: clinical effects and molecular mechanisms. Ann Med 34(3): 217-224, (2002).;;van der Kraan P.M., et al., Anabolic and destructive mediators in osteoarthritis. Curr Opin Clin Nutr Metab Care,3:205-211, 2000.;;Verdu et al., Cell-autonomous regulation of cell and organ growth in Drosopholia by Akt/PKB; Nat cell Biol 1:500-505 (1999).;;Ward, S.G., et al., Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol. Aug. ;3(4):426-434, (2003).;;Warner, T.D. et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 96:7563-7568, (1999).;;Wong B.R., et al., Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13:743-762, 2004.;;Yajima, H., et al., Isohumulones, Bitter Acids Derived From Hops, Activate Both Peroxisome Proliferator-Activated Receptor Alpha and Gamma and Reduce Insulin Resistance. J Biol Chem, 279: 33456-33462, (2004).;;Yamada, T., et al., Association with B-cell antigen cell antigen receptor with protein-tyrosine kinase-P72(Syk) and activation by engagement of membrane IgM; Eur. J. Biochem. 213: 455-459, (1993).;;Yamauchi, T., et al., The mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor gamma (PPARgamma) Deficiency and PPARgamma Agonist Improve Insulin Resistance; J Biol Chem 276(44): 41245-41254, (2001).;;Yang, W. S., et al., Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin; J Clin Endocrinol Metab 86(8): 3815-3819, (2001).;;""Information on arthrotrimtm product"", downloaded from Internet Aug. 30, 2002.;;""Information on Zyflamend and Zyflamend PM"", downloaded from Internet Aug. 30, 2002.;;""Information on Hops and Beer Flavours"", downloaded from internet Feb. 15, 2005.;;Anto, et al. Pharm. Pharmacol. Comm. 4:103-106 (1998).;;Bermejo, et al. Rev. Esp. Enferm. Dig. 95: 621-624 and 625-628 (2003).;;Brown, et al. J. Chem. Soc. 545 (1959).;;Byrne, et al. J. Chem. Soc. (c):2810 (1971).;;Carroccio, et al. Clin. Chem. 49:861-867 (2003).;;Carson, j. Am. Chem. Soc. 73:1850-1851 (1951).;;Chandra, et al. Indian J. Medical Research 60(1):138-142 (1972).;;Charlier, et al. Eur. J. Med. Chem. 38:645-659 (2003).;;Chou, et al. Eur. J. Biochem. 115:207-216 (1981).;;Chou, et al. Adv enzyme regul 22:27-55 (1984).;;Chou, et al. J. Biol. Chem. 252:6438-6442 (1977).;;Chou, et al. J. Theor. Biol. 35:285-297 (1972).;;Chou, et al. Trends Pharm. Sci. 4:450-454 (1983).;;Chou, j. Theor. Biol. 59:253-276 (1976).;;Cohen, P., Perspectives, 2002 Nature Publishing Group, vol. 1, pp. 309-315.;;Costa, et al. Digest. Liver Dis. 35:642-647 (2003).;;Davies, WL. Abstract-Fertiliser, Feeding stuffs and Farm Supplies J. 11:694 (1926).;;Ding, et al. Biochem. Biophy. Res. Comm. 261:218-223 (1999).;;Friedman, et al. J Cutan Med. Surg. 6(5):449-459 (2002).;;Gerhäuser, C., European Journal of Cancer 41 (2005), pp. 1941-1954.;;Gilani, A.H., Phytotherapy Research, 13 (1999), pp. 665-669.;;Goldstein, et al. Am. J. Gastroenterol. 96:1019-1027 (2001).;;Halter, et al. Gut 49:443-453 (2001).;;Hamberg, et al. J. Bio. Chem. 246:6713-6721 (1971).;;Huang, et al. Cancer Res. 51:813-819 (1991).;;International Search Report for PCT/US02/19617.;;International Search Report for PCT/US04/16043.;;International Search Report for PCT/US06/30920.;;Jach, Przegl Dermatol. 65(4):379-382 (1978).;;Kaltner, D., Untersuchungen zur Ausbildung des Hopfenaromas and technologische MaBnahmen zur Erzeugung hopfenaromatischer Biere, Technische Universitat Munchen, (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-AH31. (English Translation of cover page, pp. 1-2, tables on pp. 30, 78, 122, and p. 142.;;Kanematsu, et al. J Bone Miner Res 12(11):1789-1796 (1997).;;Lopes, Curr. Med Res Opin. 8:145-149 (1982).;;Meling, et al. Scand. J. Gastroenterol. 31:339-344 (1996).;;Noreen, et al. J. Nat. Prod 61:2-7 (1998).;;Pairet, et al. Inflamm. Res 47, Supplement 2s93-s101 (1998).;;Panglisch, monafsschrift fuer brauwissen schaft, 1990, 43(1), 4-16.;;Pippa, et al. Scand. J. Gastroenterol. Suppl. 167:32-35 (1989).;;Plewig, et al. J Invest. Dermatol. 65(6):532-536 (1975).;;Poullis, et al. J. Gastroenterol. Hepatol. 18:756-762 (2003).;;Provital Group, Rosemary-eco Botany, 2007, 9 pages.;;Ringbom, et al. J. Nat Prod 61:1212-1215 (1998).;;Røseth, digest. Liver Dis. 35:607-609 (2003).;;Schjerven, et al. Br. J. Dermatol. 149:484-491 (2003).;;Shah, et al. Gut 48:339-346 (2001).;;Shimamura, et al. Biochem. Biophys. Res. Comm. 289:220-224 (2001).;;Shureiqi, et al. Cancer res. 61:6307-6312 (2001).;;Sivri, fundam. Clinic. Pharmacol. 18:23-31 (2004).;;Smith, et al., Natural Foam Stabilizing and Bittering Compounds Derived From Hops, Journal of the American Society of Brewing Chemists, vol. 56, No. 2, 1998, pp. 52-57.;;Subbaramaiah, et al. Cancer Res. 60:2399-2404 (2000).;;Suh, et al. Cancer Res. 58:717-723 (1988).;;Tagashira, et al., Biosci. Biotech. Biochem. 59(4):740-742 (1996).;;Thomas m. Newmark and paul schulick, Beyond Aspirin nature's answer to arthritis, cancer & alzheimer's disease, hohm press (2000) release 7; pp. 147-151, 248.;;Tibble, et al. Drugs Today 37:85-96 (2001).;;Tibble, et al. Gut 45:362-366 (1999).;;Tobe, et al. Biosci. Biotech. Biochem 61(1):158-159 (1997).;;Vanhoenacker, et al., Analysis of iso-alpha-acids and reduced iso-alpha-acids in beer by direct injection and liquid chromatography with ultraviolet absorbance detection or with mass spectrometry, Journal of Chromatography, vol. 1035, No. 1, (Apr. 30, 2004), pp. 53-61.;;Warner, et al. Proc Natl Acad Sci USA 96:7563-7568 (1999).;;Yamamoto, et al. Abstract-Prostaglandins & Other Lipid Mediators 59:1-235 (1999).;;Yamamoto, FEBS Letters 465:103-106 (2000).;;Yui, et al. Biol. Pharm. Bull. 26:753-760 (2003).;;Supplementary Partial European Search Report for EP Application No. 05723895.8 (5 pages).;;Written Opinion for related PCT Application No. PCT/US06/30920.;;Wymann, et al. Phosphoinositide 3-Kinase gamma: a key modulator in inflammation and allergy, Biochemical Society Transactions, (Feb. 2003), vol. 31, No. Pt 1, pp. 275-280, Ref: 54.;;Dafallah, et al., Investigation of the anti-inflammatory activity of Acacia nilotica and Hibiscus sabdariffa, The American Journal of Chinese Medicine (1996), vol. 24, No. 3-4, pp. 263-269.",ACTIVE
95,NZ,A,NZ 601696 A,038-782-730-122-308,2014-02-28,2014,NZ 60169608 A,2008-12-10,US 1250607 P;;NZ 58595808 A,2007-12-10,"Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith","ABSTRACT - 601696 The disclosure relates to the use of a composition for manufacturing a medicament for modulating a protein kinase in a mammal in need thereof, said use comprising formulating the medicament for administration to the mammal, wherein the medicament comprises a therapeutically effective amount of a substituted 1,3-cyclopentadione compound, wherein the protein kinase modulated is selected from the group consisting of ATK, FGFR3, c-Jun NH2-terminal kinase-3 (JNK3), Phosphoinositide-dependent kinase (PDK) and phosphatidylinositol-3-kinase (PI3K), and wherein the substituted 1,3-cyclopentadione compound is hexahydroisoalpha acids, and wherein composition may further comprise a pharmaceutically acceptable excipient selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintergrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents, as well as further members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,,https://lens.org/038-782-730-122-308,Patent Application,no,0,0,1,1,0,,A61K38/00;;A61K31/12;;A61K45/06,,0,0,,,,DISCONTINUED
96,WO,A1,WO 2009/076428 A1,128-179-116-329-460,2009-06-18,2009,US 2008/0086208 W,2008-12-10,US 1250607 P,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH","Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.",METAPROTEOMICS LLC;;TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,,https://lens.org/128-179-116-329-460,Patent Application,yes,6,3,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00,,1,0,,,See also references of EP 2229178A4,PENDING
97,CA,A1,CA 2708613 A1,112-113-377-263-997,2009-06-18,2009,CA 2708613 A,2008-12-10,US 1250607 P;;US 2008/0086208 W,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH","Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,,https://lens.org/112-113-377-263-997,Patent Application,no,0,1,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00,,0,0,,,,DISCONTINUED
98,CN,A,CN 101969972 A,028-785-629-616-611,2011-02-09,2011,CN 200880126170 A,2008-12-10,US 2008/0086208 W;;US 1250607 P,2007-12-10,"Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith","Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.",METAPROTEOMICS LLC,BLAND JEFFREY S;;PACIORETTY LINDA M;;BRIAN CARROLL;;VEERA KONDA;;TRIPP MATTHEW L;;BABISH JOHN G;;GARY DARLAND;;JAMES TRAUB;;DENNIS EMMA;;ANU DESAI,,https://lens.org/028-785-629-616-611,Patent Application,no,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00,,0,0,,,,DISCONTINUED
99,MX,A,MX 2010006425 A,148-118-937-088-963,2010-08-31,2010,MX 2010006425 A,2008-12-10,US 1250607 P;;US 2008/0086208 W,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH.","Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.",METAPROTEOMICS LLC,KONDA VEERA;;DESAI ANU;;BLAND JEFFREY S;;TRIPP MATTHEW L;;BABISH JOHN G;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,,https://lens.org/148-118-937-088-963,Patent Application,no,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00,,0,0,,,,DISCONTINUED
100,AU,A1,AU 2008/335156 A1,181-742-243-652-844,2009-06-18,2009,AU 2008/335156 A,2008-12-10,US 1250607 P;;US 2008/0086208 W,2007-12-10,"Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith",,METAPROTEOMICS LLC,BLAND JEFFREY S;;PACIORETTY LINDA M;;CARROLL BRIAN;;KONDA VEERA;;TRIPP MATTHEW L;;BABISH JOHN G;;DARLAND GARY;;TRAUB JAMES;;EMMA DENNIS;;DESAI ANU,,https://lens.org/181-742-243-652-844,Patent Application,no,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00,,0,0,,,,DISCONTINUED
101,ZA,B,ZA 201004687 B,162-419-917-878-77X,2011-03-30,2011,ZA 201004687 A,2010-07-02,US 1250607 P;;US 2008/0086208 W,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER,ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH",,METAPROTEOMICS LLC,EMMA DENNIS;;PACIORETTY LINDA M;;TRAUB JAMES;;CARROLL BRIAN;;DARLAND GARY;;DESAI ANU;;KONDA VEERA;;BLAND JEFFREY S;;BABISH JOHN G;;TRIPP MATTHEW L,,https://lens.org/162-419-917-878-77X,Granted Patent,no,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,,,0,0,,,,ACTIVE
102,KR,A,KR 20100131969 A,106-896-337-408-676,2010-12-16,2010,KR 20107015368 A,2008-12-10,US 1250607 P,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH",,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS,,https://lens.org/106-896-337-408-676,Patent Application,no,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K31/122;;A61K31/12;;A61K38/16;;A61P35/00,,0,0,,,,DISCONTINUED
103,EP,A1,EP 2229178 A1,045-833-932-686-073,2010-09-22,2010,EP 08859091 A,2008-12-10,US 2008/0086208 W;;US 1250607 P,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH",,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS A,,https://lens.org/045-833-932-686-073,Patent Application,yes,0,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00;;A61K31/12;;A61K45/06;;A61P35/00,,0,0,,,,DISCONTINUED
104,EP,A4,EP 2229178 A4,193-877-338-357-702,2011-03-09,2011,EP 08859091 A,2008-12-10,US 2008/0086208 W;;US 1250607 P,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH",,METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN;;TRAUB JAMES;;PACIORETTY LINDA M;;EMMA DENNIS A,,https://lens.org/193-877-338-357-702,Search Report,no,4,0,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K38/00;;A61K31/12;;A61K45/06;;A61P35/00,,1,0,,,See also references of WO 2009076428A1,DISCONTINUED
105,US,A1,US 2010/0137449 A1,012-672-901-890-176,2010-06-03,2010,US 33188708 A,2008-12-10,US 33188708 A;;US 1250607 P,2007-12-10,"SUBSTITUTED 1,3-CYCLOPENTADIONE MULTI-TARGET PROTEIN KINASE MODULATORS OF CANCER, ANGIOGENESIS AND THE INFLAMMATORY PATHWAYS ASSOCIATED THEREWITH","Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.",METAPROTEOMICS LLC,TRIPP MATTHEW L;;BABISH JOHN G;;BLAND JEFFREY S;;KONDA VEERA;;DESAI ANU;;DARLAND GARY;;CARROLL BRIAN J;;TRAUB JAMES S;;PACIORETTY LINDA M;;EMMA DENNIS,METAPROTEOMICS LLC (2008-01-14),https://lens.org/012-672-901-890-176,Patent Application,yes,99,2,11,11,0,A61K31/12;;A61K31/12;;A61K45/06;;A61K45/06;;A61P9/00;;A61P9/10;;A61P35/00;;A61P43/00,A61K31/122;;A61P9/10;;A61P35/00,514/685;;514/689;;514/690,0,0,,,,DISCONTINUED
